AUTHOR INDEX

Arthritis & Rheumatism, Volume 44, Numbers 1–12, 2001

A

Abeles M, 653
Abrahamowicz M, 2331
Abramson SB, 578, 1203, 1237, 1587
Adachi JD, 202
Adachi M, 2512
Adachi T, 2160
Adachi Y, 1127
Adlam DJ, 585
Adu D, 921
Agarwal S, 608, 2311
Ahern MJ, 105, 245, 343
Ahmed S, 243
Ahn CW, 981
Aiba-Masago S, 693
Aigner T, 1304, 1943, 2046, 2777
Ainsworth J, 2633
Akahoshi M, 2097
Alaeddine N, 1633
Alansari A, 2358
Alarcón GS, 361, 981, 2797
Alcami J, 1382
Al-Hashimi I, 693
Aliabadi P, 2065
Alikasifoglu M, 2387
Allcock RJ, 1660
Allen NB, 912
Alonso A, 307
Altman RD, 1471, 2531
Alvarez I, 1677
Alves H, 1261
Amakawa R, 419
Amano T, 550
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis, 1496
American College of Rheumatology Audiovisual Aids Subcommittee, 513
Amft N, 2633
Amick BC III, 1184
Amin AR, 578
Amoura Z, 488
Anderson CJ, 737
Anderson JJ, 1720, 1876
Anderson P, 884, 2879
Ando S, 296
Andrews B, 653
Antonen J, 176
Aoki H, 1056
Aono H, 1545
Apparailly F, 1444
Appelboom T, 2371
Aquilar MB, 1359
Aratani S, 1545
Archer CW, 1795
Arend WP, 451, 2224
Aringer M, 1721
Armour KE, 2185, 2790
Armour KJ, 2185, 2790
Arner EA, 1401
Arnett FC, 893, 1359, 1855
Artlett CM, 2945
Asano Y, 1363
Astin P, 1177, 2932
Atiquzzaman BM, 169
Atkinson JP, 995
Attur MG, 578
Aupperle KR, 676, 1897
Auriola S, 2201
Aviña-Zubieta A, 1331

B

Bacon PA, 2707
Badger AM, 128
Baeten D, 186, 931, 2255, 2938
Baethge BA, 361
Baici A, 1819
Baker AH, 1444
Bakkaloglu A, 2387
Balandraud N, 535
Balestrieri G, 2870
Ballara S, 2055
Balsa A, 1261
Bank RA, 2562
Barclay L, 1808
Bárdos T, 682
Barge RMY, 754
Barland P, 1713
Baron D, 2485
Baron G, 1876
Baron M, 1351
Baroni SS, 2653
Barr SG, 2342, 2350
Barr W, 653
Barrett EM, 1033
Barrett JH, 239, 802
Bartling G, 2392
Bartolucci AA, 2797
Barton A, 61
Bastian HM, 981, 2797
Bayliss MT, 1455, 1795
Becker A, 2492
Bedocs N-M, 1149
Beer Y, 2176
Beers J, 1089
Beeton C, 2263
Béhier J-M, 180
Behney KM, 2367
Bellamy N, 1351
Bello JA, 1713
Belmont HM, 1203
Benbow U, 1096
Benderdour M, 73
Benedito-Silva AA, 222
Benito P, 2761
Benjamin S, 940
Bennett BL, 1897
Bennett PH, 1170
Berardi S, 1819
Berdah L, 2539
Berden JHM, 1320
Berg EL, 1428
Berman B, 819
Bernitt K, 528
Bernstein B, 1411
Berthelot JM, 2485
Bertouch JV, 343
Bessard G, 1143
Bessette L, 1184
Bestmann L, 2213
Bevilacqua C, 1800
Bezemer PD, 1965
Bhattacharyya PK, 1713
Bheekha-Escura R, 1438
Bianchi DW, 1848, 2107
Bijlsma JWJ, 3, 754, 2562
Birch S, 819
Bird PA, 2138
Biroc SL, 703
Bitsch A, 1908
Bitzan P, 266
Bjarnason I, 2728
Black CM, 662, 712, 2706
Blake DR, 1534
Blake S, 128
Blakely KW, 2235
Blanco-Favela F, 866
Blank M, 1484
Bläß S, 761
Blobel CP, 2046
Block JA, 202
Block T, 486
Blom HJ, 2525
Bluestone J, 1730
Blum A, 2285
Blumberg B, 486
Boers M, 1052, 2242, 2703
Bohlig AM, 1599
Böhm BB, 2046
Boiardi L, 1155
Boivin GP, 794
Bolstad AI, 638
Bombardieri s, 245
Bona CA, 893
Bonney EA, 2944
Bordji K, 351
Bottaro DP, 73
Botton E, 2485
Bou-Gharios G, 712
Bout A, 48, 570
Bowman SJ, 2633
Boyle DL, 1897
Bozza A, 1155
Bozzolo E, 2841
Bradbury L, 1396
Brandt J, 2936
Brandt KD, 1473, 1786, 2451
Braun J, 2936
Braunstein N, 1229
Brayer J, 693
Breban M, 1964
Breedveld FC, 41, 48, 570, 754, 1515, 2029
Brennan F, 1754
Bresnihan B, 782, 1744, 1761, 2263
Bridges SL Jr., 2275
Brik R, 1416
Brinkerhoff CE, 1096, 2296
Brinson DC, 2768
British Paediatric Rheumatology Study Group, 802, 1782
Brophy S, 1396
Brown J, 202
Brown MA, 1396
Brucato A, 243, 1832
Bruner GR, 1122, 2807
Bruns A, 1962
Buckley CD, 2633
Buckley MJ, 608
Buckton J, 2697
Buer J, 2392
Bukhari M, 1033, 1248
Bulpitt K, 432
Bultink IEM, 979
Burdick MD, 31
Burgkart R, 2072
Burkhardt H, 2046, 2402
Burmester GR, 151, 761, 1962, 2435, 2620
Bush TM, 2111
Butler DM, 451
Buyon JP, 1203, 1466, 1723

C

Caballero A, 307
Cacoub P, 1836, 2118
Caillat-Zucman S, 2118
Calabrese LH, 912
Caldwell JR, 1587, 1984
Calin A, 180, 1396
Callahan LF, 1587
Callan MFC, 2038
Camejo G, 2761
Camera M, 2870
Campbell IK, 442
Campo E, 1387
Cañete JD, 66
Cannon GW, 1984
Cantagrel A, 1736
Cantini F, 1155, 2933
Cao S, 1438
Caputi AP, 2909
Caravatti M, 53
Cardellach F, 1387
Cardon LR, 1396
Carette S, 1351
Carofano W, 202
Carossino A, 1865
Carpentier PH, 1143
Carrère S, 2296
Carson DA, 772
Carsons S, 2572

AUTHOR INDEX

Arthritis & Rheumatism, Volume 44, Numbers 1–12, 2001

A

Abeles M, 653
Abrahamowicz M, 2331
Abramson SB, 578, 1203, 1237, 1587
Adachi JD, 202
Adachi M, 2512
Adachi T, 2160
Adachi Y, 1127
Adlam DJ, 585
Adu D, 921
Agarwal S, 608, 2311
Ahern MJ, 105, 245, 343
Ahmed S, 243
Ahn CW, 981
Aiba-Masago S, 693
Aigner T, 1304, 1943, 2046, 2777
Ainsworth J, 2633
Akahoshi M, 2097
Alaeddine N, 1633
Alansari A, 2358
Alarcón GS, 361, 981, 2797
Alcami J, 1382
Al-Hashimi I, 693
Aliabadi P, 2065
Alikasifoglu M, 2387
Allcock RJ, 1660
Allen NB, 912
Alonso A, 307
Altman RD, 1471, 2531
Alvarez I, 1677
Alves H, 1261
Amakawa R, 419
Amano T, 550
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis, 1496
American College of Rheumatology Audiovisual Aids Subcommittee, 513
Amft N, 2633
Amick BC III, 1184
Amin AR, 578
Amoura Z, 488
Anderson CJ, 737
Anderson JJ, 1720, 1876
Anderson P, 884, 2879
Ando S, 296
Andrews B, 653
Antonen J, 176
Aoki H, 1056
Aono H, 1545
Apparailly F, 1444
Appelboom T, 2371
Aquilar MB, 1359
Aratani S, 1545
Archer CW, 1795
Arend WP, 451, 2224
Aringer M, 1721
Armour KE, 2185, 2790
Armour KJ, 2185, 2790
Arner EA, 1401
Arnett FC, 893, 1359, 1855
Artlett CM, 2945
Asano Y, 1363
Astin P, 1177, 2932
Atiquzzaman BM, 169
Atkinson JP, 995
Attur MG, 578
Aupperle KR, 676, 1897
Auriola S, 2201
Aviña-Zubieta A, 1331

B

Bacon PA, 2707
Badger AM, 128
Baeten D, 186, 931, 2255, 2938
Baethge BA, 361
Baici A, 1819
Baker AH, 1444
Bakkaloglu A, 2387
Balandraud N, 535
Balestrieri G, 2870
Ballara S, 2055
Balsa A, 1261
Bank RA, 2562
Barclay L, 1808
Bárdos T, 682
Barge RMY, 754
Barland P, 1713
Baron D, 2485
Baron G, 1876
Baron M, 1351
Baroni SS, 2653
Barr SG, 2342, 2350
Barr W, 653
Barrett EM, 1033
Barrett JH, 239, 802
Bartling G, 2392
Bartolucci AA, 2797
Barton A, 61
Bastian HM, 981, 2797
Bayliss MT, 1455, 1795
Becker A, 2492
Bedocs N-M, 1149
Beer Y, 2176
Beers J, 1089
Beeton C, 2263
Béhier J-M, 180
Behney KM, 2367
Bellamy N, 1351
Bello JA, 1713
Belmont HM, 1203
Benbow U, 1096
Benderdour M, 73
Benedito-Silva AA, 222
Benito P, 2761
Benjamin S, 940
Bennett BL, 1897
Bennett PH, 1170
Berardi S, 1819
Berdah L, 2539
Berden JHM, 1320
Berg EL, 1428
Berman B, 819
Bernitt K, 528
Bernstein B, 1411
Berthelot JM, 2485
Bertouch JV, 343
Bessard G, 1143
Bessette L, 1184
Bestmann L, 2213
Bevilacqua C, 1800
Bezemer PD, 1965
Bhattacharyya PK, 1713
Bheekha-Escura R, 1438
Bianchi DW, 1848, 2107
Bijlsma JWJ, 3, 754, 2562
Birch S, 819
Bird PA, 2138
Biroc SL, 703
Bitsch A, 1908
Bitzan P, 266
Bjarnason I, 2728
Black CM, 662, 712, 2706
Blake DR, 1534
Blake S, 128
Blakely KW, 2235
Blanco-Favela F, 866
Blank M, 1484
Bläß S, 761
Blobel CP, 2046
Block JA, 202
Block T, 486
Blom HJ, 2525
Bluestone J, 1730
Blum A, 2285
Blumberg B, 486
Boers M, 1052, 2242, 2703
Bohlig AM, 1599
Böhm BB, 2046
Boiardi L, 1155
Boivin GP, 794
Bolstad AI, 638
Bombardieri s, 245
Bona CA, 893
Bonney EA, 2944
Bordji K, 351
Bottaro DP, 73
Botton E, 2485
Bou-Gharios G, 712
Bout A, 48, 570
Bowman SJ, 2633
Boyle DL, 1897
Bozza A, 1155
Bozzolo E, 2841
Bradbury L, 1396
Brandt J, 2936
Brandt KD, 1473, 1786, 2451
Braun J, 2936
Braunstein N, 1229
Brayer J, 693
Breban M, 1964
Breedveld FC, 41, 48, 570, 754, 1515, 2029
Brennan F, 1754
Bresnihan B, 782, 1744, 1761, 2263
Bridges SL Jr., 2275
Brik R, 1416
Brinkerhoff CE, 1096, 2296
Brinson DC, 2768
British Paediatric Rheumatology Study Group, 802, 1782
Brophy S, 1396
Brown J, 202
Brown MA, 1396
Brucato A, 243, 1832
Bruner GR, 1122, 2807
Bruns A, 1962
Buckley CD, 2633
Buckley MJ, 608
Buckton J, 2697
Buer J, 2392
Bukhari M, 1033, 1248
Bulpitt K, 432
Bultink IEM, 979
Burdick MD, 31
Burgkart R, 2072
Burkhardt H, 2046, 2402
Burmester GR, 151, 761, 1962, 2435, 2620
Bush TM, 2111
Butler DM, 451
Buyon JP, 1203, 1466, 1723

C

Caballero A, 307
Cacoub P, 1836, 2118
Caillat-Zucman S, 2118
Calabrese LH, 912
Caldwell JR, 1587, 1984
Calin A, 180, 1396
Callahan LF, 1587
Callan MFC, 2038
Camejo G, 2761
Camera M, 2870
Campbell IK, 442
Campo E, 1387
Cañete JD, 66
Cannon GW, 1984
Cantagrel A, 1736
Cantini F, 1155, 2933
Cao S, 1438
Caputi AP, 2909
Caravatti M, 53
Cardellach F, 1387
Cardon LR, 1396
Carette S, 1351
Carofano W, 202
Carossino A, 1865
Carpentier PH, 1143
Carrère S, 2296
Carson DA, 772
Carsons S, 2572

Carter RA, 985
Casassus P, 666
Casciola-Rosen L, 389, 2376
Casiano CA, 2642
Cassarino DF, 723
Catelli L, 243, 1832
Caterson B, 2586
Catoggio L, 1351
Catravas JD, 902
Cattan D, 163
Catterall JB, 2296
Cavazzana I, 1832
Cawston TE, 1620, 2084, 2263, 2296
Ceponis A, 1908
Chabaud M, 1293
Chaisson CE, 1105
Chakraborty R, 893
Chalès G, 2485
Chalmers IM, 1351
Chambers MG, 1455
Chamorro M, 772
Chana JK, 1534
Chandrasekaran R, 682
Chang RW, 212
Charles P, 1968
Charlotte F, 2118
Chatterjee S, 1359
Chávez-Rueda KA, 866
Cheema GS, 1313
Chen S, 2879
Cheung NT, 1529
Chevalier X, 2134
Cho C-S, 561
Cho M, 1359
Cho M-L, 561
Chong L, 1455
Choquette D, 735
Choy EHS, 1993
Christner PJ, 2945
Ciancio G, 1155
Ciboddo G, 2841
Cid MC, 1387
Cimaz R, 243, 1832
Ciocca M, 1139
Clancy R, 1203
Clapp C, 1331
Clark SH, 723
Clarke AE, 2331
Claudepierre P, 2134
Clayton JL, 2413
Clements PJ, 653
Clerc D, 2458
Clot J, 1281
Coblyn JS, 1048
COBRA Trial Group, 2242, 2703
Cohen M, 492
Cohen P, 666, 2118
Cohen S, 1984
Collier D, 653
Combe B, 1281, 1736
Conaghan PG, 1177, 2932
Conneely OM, 782
Connors MA, 31
Cooke CJ, 541
Cooper SM, 1966
Copel JA, 1723
Corke KP, 1540
Corr M, 772
Correa-Rotter R, 202
Corris PA, 1660
Côté R, 2331
Court-Payen M, 2018
Cover P, 1455
Cox AE, 389, 2376
Cox L, 1455
Cracowski J-L, 1143
Crayton H, 2862
Creighton-Achermann L, 1633, 2768
Criswell LA, 618
Crocker J, 2633
Crofford LJ, 1230, 2125
Crook S, 1149
Cruz J, 1331
Csernok E, 469
Cuadrado M-J, 2467
Cuello C, 343
Cummins P, 1587
Cunnane G, 1744, 2263, 2937
Cupps TR, 2862
Curnow SJ, 2633
Cutler BL, 1599
Cutolo M, 493
Cuvelier C, 186
Cuzzocrea S, 2909
Czachur M, 202

D

Daifotis A, 202
Dal Cin E, 2841
Dang H, 693
Dann P, 2492
D'Arcy CA, 1717
Dart RC, 2449
Daurès J-P, 1736
D'Auria F, 2841
Dave MN, 578
David L, 2214
Davies DH, 1917
Davies N, 802
Dávila M, 1139
Davis JC, 912
Davis JRE, 2358
Davison C, 2477
Dawes PT, 1529
De Bari C, 85, 1608, 1928
de Boo TM, 1515, 2525
de Crombrugghe B, 712
de Jong BAW, 41
De Keyser F, 186, 761, 2255, 2938
de Konig MHMT, 979
de la Concha EG, 1261
De Lacroix I, 1836
de Rooij D-JRAM, 1515
De Sarro A, 2909
De Vos M, 186
de Waal Malefijt MC, 1254
Degnan BA, 1620, 2296
DeGroot J, 2562
del Rincón I, 2737
Del Soldato P, 2185
Dell'Accio F, 85, 1608, 1928
Dell'Antonio G, 2841
Delmas PD, 202
Demaille J, 163
Demetter P, 186
Demols P, 2371
Dempster H, 1768
Deng C, 397
Denhardt DT, 578
Dennis G, 1114, 1336
Denton CP, 712
Deodhar A, 170
Derry CJ, 1917
Desmoulins F, 2458
Devadas A, 2633
Devauchelle V, 2485
Di Battista JA, 595
Diamond B, 1730
Dieppe PA, 1786, 2450
Dijkmans BAC, 979, 997, 1476, 1515, 1965
Dinant HJ, 979
Distler O, 1865, 2665
Dobado-Berrios P-M, 2467
Dodge GR, 1089
Dodig TD, 723
Doherty M, 1786
Domingo C, 163
Domingo MA, 2367
Dong X, 2367
Doni A, 2841
Donn RP, 802, 1782, 2358
Dorger M, 1420
Doria A, 1832
Dörner T, 626, 2620, 2715
Dougados M, 180, 1736, 1876, 1964, 2539
Drayson M, 921
Drew R, 1043
du Berger R, 2331
Dubois A, 1736
Dugo L, 2909
Dumortier T, 202
Dunlop DD, 212
Dunn G, 1033
Dunne SM, 231
Dusi S, 2653
Dwek R, 486

E

Eberspaecher H, 712
Ebling FM, 432
ECHODIAH Investigators Study Group, 2539
Eckhoff PJ, 2235
Eckstein F, 2072, 2556
Edwards CK III, 2146
Edwards ET, 2862
Eggerer J, 1808
Eguchi K, 884
Eldor A, 1484
El-Gabalawy H, 1689
Eliaou J-F, 1281, 1736
Elliott S-F, 2084
Ellman M, 1351
Emery P, 1177, 2024, 2112, 2932
Emkey RD, 202
Emond S, 196
Engel J-M, 761
Engleman EP, 1495
Englmeier K-H, 2072, 2556
Enyedy EJ, 1114, 1336
Erkan D, 1466
Erlendsson K, 2247
Eronen M, 487, 647
Escalante A, 2737
Esdaile JM, 2331
Eskildsen MA, 1401
Espinola R, 876
Esteban M-J, 1387
Etienne S, 2285
Evans S, 1105
Ezendam NPM, 2029
Ezzo J, 819

F

Faccini A, 1800
Faden D, 1832
Faehndrich T-P, 331
Fahmi H, 595
Fam AG, 231
Familian A, 997
Farhan A, 802
Fass DN, 463
Fazou C, 2038
Fazzini F, 2841
Fearon U, 2024
Feghali CA, 1654
Feinglass S, 170
Feldman BM, 1768
Feldmann M, 451, 1215, 2055
Felson DT, 811, 1105, 1477, 1720, 1876, 2065
Fenlon D, 1841
Fenton JW II, 1370
Fermor B, 2078
Fernandes JC, 2320
Fernandez AM, 2235
Fernandez-Arquero M, 1261
Ferrari SL, 196
Fertig N, 1663
Fervenza FC, 2836
Fessler BJ, 981, 2797
Fibbe WE, 754
Fink C, 2078
Finkel TH, 1775
Finnegan A, 682
Firestein GS, 676, 1897
FitzGerald O, 782, 1744, 1761, 2263
Fleck M, 964, 2146
Font C, 1387
Fort J, 1587
Fortin PR, 2331
Fossel AH, 1184
Fournel-Gigleux S, 351
Fox R, 1984
Fox TM, 2448
Francès C, 488
Franceschini F, 1832
Fransen J, 53
Franz JK, 151
Fraser A, 2024
Frassi M, 1832

Freeman GL, 2737
Freemont AJ, 1540
Frémeaux-Bacchi V, 1836
French AR, 523
French Vasculitis Study Group, 666
Friedman AW, 981, 2797
Friedman DM, 1723
Friemann J, 2492
Frigge ML, 2247, 2548
Frith JC, 2201
Fritze O, 151
Fujimoto M, 1363
Fukamizu A, 1545
Fukuda K, 2097
Furst DE, 653, 1351, 1848, 1984
Furuhara S, 419
Furukawa H, 384
Furuya T, 1003
Fye KH, 912

G

Gabay C, 451
Gabriel SE, 523, 1504
Gabrielli A, 2653
Galindo M, 1382, 1667
Gallagher K, 1411
Gallagher PJ, 1534
Galle PR, 1209
Gambari PF, 1832
García-del-Portillo, 1677
García-Martínez A, 1387
Garnero P, 196
Gassner R, 608, 2311
Gay RE, 676, 703, 956, 1744, 1865, 2665
Gay S, 676, 703, 1744, 1865, 2665
Gayraud M, 666, 2943
Gebhard PM, 1304, 2777
Gehrsitz A, 2777
Geirsson AJ, 2247
Gejyo F, 339
Gelber AC, 389
Gelse K, 1943
Genovese MC, 1525, 1977
Georganas C, 2899
Gerard D, 682
Gérard HC, 1689
Gerlag DM, 1897
Gershoni-Baruch R, 1416
Ghillani P, 2118
Ghirardello A, 1832
Giannini EH, 794
Gibbon, WW, 2932
Gibofsky A, 169
Giesendorf BAJ, 2525
Gigley JP, 451
Gillet P, 2285
Girard C, 120
Glant TT, 682
Glaser C, 2072, 2556
Glass DN, 794
Glass JM, 2125
Godeau P, 1836
Goding J, 1071
Goh, E, 2932
Gohlke F, 331
Gokhale Y, 2939
Goldbach-Mansky R, 1689
Gómez-Casanovas E, 66
Goossens PH, 48, 570
Goppelt-Struebe M, 1698
Gordon PA, 242
Goronzy JJ, 13
Gottenberg J-E, 2458
Goulet J-R, 735
Goupille P, 1736
Gouze J-N, 351
Gowen M, 128
Gracie JA, 1481
Grady D, 811
Granfors K, 931, 1209
Graninger W, 1721
Grant SFA, 2247
Grassi F, 1800
Grau JM, 1387
Gray-McGuire C, 2807
Green M, 1177
Green P, 1754
Greenspan SL, 196
Greenwald RA, 1043
Greer S, 1998
Greidinger EL, 368
Griffith L, 1954
Grodzicky T, 2331
Grodzinsky AJ, 1401
Gröger M, 266
Grom AA, 794
Gross WL, 469, 1887
Grøver SA, 2331
Gruber BL, 202
Gu J, 931
Gudbjartsson DF, 2247
Gudmundsson M, 2247
Guedez YB, 2413
Guidolin D, 1800
Guiducci S, 2665
Guilak F, 2078
Guillaume M-P, 2943
Guillevin L, 666, 2943
Guillien F, 1836
Guis S, 535
Gül A, 239, 2693
Gulberti S, 351
Gulcher JR, 2247, 2548
Gündüz OH, 1663
Gunnlaugsdóttir B, 2247
Guppy MJ, 662, 2706
Gussin HAE, 376

H

Haagsma CJ, 2525
Hack CE, 997
Hadhazy V, 819
Hadler NM, 1971
Hahn BH, 432
Hahn TJ, 2572
Haibel H, 2936
Haines GK III, 21, 1568, 2899
Haire C, 2235
Hajeer AH, 239, 1529, 2358, 2693
Häkkinen A, 515
Hakoda M, 1003, 1226
Hale G, 1998
Hall PH, 1273
Hall T, 1122
Hamada H, 2211
Hamburger J, 2633
Hamersma J, 1396
Hamilton JA, 111, 2459
Hammer M, 2679
Hamuryudan V, 2686
Han J, 286
Han S, 1438
Hanash SM, 397
Hanemaaijer R, 1908
Hannonen P, 515
Hansen A, 626, 2620
Hanson RL, 1170
Hansson A-S, 2402
Hanyuda M, 2512
Hara M, 1716
Haralambous S, 2888
Harigai M, 1716
Harley JB, 1122, 2807
Harlow LA, 31
Harms H, 331
Harper KD, 2611
Harper L, 921
Harper N, 1917
Harrell RA, 1587
Harris ED Jr., 1969
Harris EN, 876
Harrison B, 323, 1248
Hart DA, 1808
Hartman M, 1515
Hashimoto S, 826, 1071, 1633
Haskard DO, 138
Hassell AB, 1529
Hasunuma T, 1013
Hata K, 339
Haugeberg G, 2941
Hausdorf G, 2435
Häuselmann H, 53
Havenga MJE, 48, 570
Hawkins F, 202
Hayem G, 1965
Hayer S, 2888
Hazleman, 1998
Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study, 2611
Heart and Estrogen/Progestin Replacement Study Research Group, 811
Heath JK, 1620
Heimbächer C, 626
Heinegård D, 2402
Helfgott S, 1048
Hellmann DB, 912, 1149
Helmy N, 2213
Hemmel M, 1304
Hendrickson J, 1775
Herman H, 180
Hernández-Rodríguez J, 1387
Herrick A, 243
Herrndorf A, 1160
Hess S, 2392
Heufelder AE, 253
Hewins P, 2851
Hiepe F, 1962, 2435
Higgins GC, 1775
Hilbert DM, 1313
Hirakata H, 2097
Hirata M, 974
Hirsch R, 794
Ho A, 2342, 2350
Hoang S, 2485
Hochberg M, 819, 2455
Hocher B, 2435
Hofbauer A, 1420
Hofbauer LC, 253
Hoffman GS, 912, 1149
Hoffman RW, 368
Hoffman S, 1370
Hoffman SJ, 128
Hogan MCE, 2836
Hohe J, 2556
Höhler T, 1209
Hollander AP, 1540, 2586
Holmdahl R, 2168, 2402
Homma MK, 260
Homma T, 296
Homma Y, 260
Honda T, 1545
Hong P, 1351
Hordon L, 1177
Hörler D, 956, 1819
Hosono O, 296
Hsu H-C, 964, 1555, 2146
Hu LT, 1401
Huang F, 931
Hudelmaier M, 2556
Hudson AP, 1689
Hudson K, 1620
Hüe S, 2118
Hug R, 1209
Hughes GRV, 242
Huizinga TWJ, 48, 570, 1515, 2525
Hulkkonen J, 176
Hull KM, 1954
Hummel K, 703
Hummel KM, 1744
Humphreys-Beher MG, 693
Hunt M, 1143
Huong DLT, 488
Hurme M, 176
Hurt-Camejo E, 2761
Hurwitz EL, 653
Hutchinson D, 2942
Hydoh F, 491
Hyhlik-Dürr A, 2072
Hyttinen M, 1908

I

Iazzetta J, 231
Ichikawa N, 1226
Ida H, 884
Ide H, 2512
Ignat GP, 376
Ihn H, 474, 731, 1363
Ilonen J, 315
Imagawa T, 794
Imbert B, 1143

Inada S, 1266
Inda SE, 618
Ingvarsson T, 2548
Inoue M, 96
International Network for Study of the Systematic Vasculitides (INSSYS), 912
Ionescu M, 2503
Isaacs JD, 1998
Ishiguro N, 2503
Ishii H, 1545
Ishiyama S, 1003
Isozaki Y, 491
Issekutz AC, 1428
Ito A, 2193
Ito S, 339
Ito T, 419, 2503
Iwai H, 419
Iwata S, 296, 2503
Iyama S, 2160

J

Jacobi A, 626, 2620
Jacobs MJM, 1515
Jacobsson LTH, 1170
Jacquet C, 1444
Jaffe M, 1599
Jain A, 1754
James JA, 1122
James WH, 1476
Jansson L, 2168
Jarošová K, 2387
Jarrousse B, 666
Jendro MC, 2679
Jiang H, 2599
Jiang Q-J, 1943
Jibiki T, 2211
Johansen JS, 826
John S, 61
Johnson K, 1071
Johnson KL, 1848, 2107
Johnson N, 2642
Johnson RW, 2446
Johnston J, 1998
Jolchine I, 180
Jolicoeur F-C, 2320
Jónsdóttir þ, 2548
Jónsson H, 2247, 2548
Jónsson HH, 2548
Jonsson R, 638
Joosten LAB, 2413
Jordan JM, 1587
Jorgensen C, 1444
Jovanovic DV, 2320
Joyal F, 735
Julkunen H, 487, 647

K

Kabir F, 2367
Kaburaki J, 737
Kabuyama Y, 260, 419
Kagawa H, 419
Kahn M-F, 1836
Kainberger F, 2888
Kaine J, 1984
Kaiser M-J, 1444
Kajiyama H, 1266
Kalden JR, 2046
Kalunian K, 2572
Kaluza W, 1209
Kamatani N, 1003, 1226, 1266, 1716
Kaminska E, 1351
Kammer GM, 1114, 1336
Kamphuis SSM, 728
Kamradt T, 2435
Kanai H, 2097
Kanazawa M, 2211
Kaneko H, 1266
Kang AH, 1775
Kapadia R, 128
Kaplan G, 819
Kaplan MJ, 397
Kaplanski G, 2118
Kaprio J, 481
Kaps C, 2392
Karim, Z, 2932
Kasama T, 2512
Kaschner S, 2620
Kasinetz L, 1416
Kato J, 2160
Kato T, 384, 838, 1056
Katrib Amel, 343
Katschke KJ Jr., 1022, 1568, 2750
Katsicas MM, 1139
Katz BP, 1786
Katz JN, 1184
Katz PP, 1194
Katz Y, 2176
Kaufman J-M, 202
Kauppi M, 241
Kavanaugh A, 2221
Kawabe Y, 884
Kawaguchi Y, 1716
Kawakami A, 884
Kawald A, 2435
Kawasaki H, 296
Kawashima M, 275, 550
Kazatchkine MD, 1836
Keino H, 1127
Keller RB, 1184
Kelly J, 2807
Kerlan-Candon S, 1281
Kern E-R, 964
Kerr G, 2118
Kerr NC, 1775
Keyßer G, 151
Khalkhali-Eilis Z, 1582
Khamashta MA, 242, 2870
Khan IM, 1795
Khoa ND, 1013
Kidder LH, 846
Kielty CM, 1855
Kiemeney LALM, 2009
Kiene M, 469
Kiener HP, 266
Kikuchi M, 339
Kikuchi S, 260
Kim H-Y, 561
Kim K-J, 1003
Kim MY, 1723
Kim W-U, 561
Kimball MD, 1855
Kingsley GH, 1993
Kirchner T, 1304
Kirkham BW, 2138
Kirveskari J, 931
Kiss R, 2371
Klarlund M, 2018
Klassen LW, 2235
Klaus JL, 703
Klausen T, 2018
Klein G, 2940
Klein R, 2435
Klocke R, 1534
Klos A, 2392
Knight C, 662, 2706
Knowler WC, 1170
Knudson CB, 2599
Knudson W, 2599
Ko F, 2572
Kobata T, 1013, 1545
Kobayashi K, 2512
Kobayashi M, 974
Koch AE, 21, 31, 1022, 1568, 2750, 2899
Koch GG, 1587
Kogawa K, 2160
Kohno Y, 2211
Kohsaka T, 2097
Kojima T, 120, 2503
Kojo S, 1127
Köller M, 856
Kollias G, 2888
Komuro H, 2768
Koné-Paut I, 163
Konttinen YT, 1908
Koseki Y, 1266
Koshy PJT, 1620, 2296
Kostense PJ, 2242
Kostoulas G, 1819
Kotake S, 1003, 1226
Kotani H, 2922
Kotaniemi A, 515
Kowal-Bielecka O, 1865, 2665
Kowalski AJ, 578
Krabbe PFM, 1515
Kraus VB, 1043
Krause A, 151
Kremer JM, 1587
Krenn V, 331
Krishnan S, 1336
Kroft JD Jr., 247
Krombach F, 1420
Kroot E-JJA, 1254
Kruithof E, 186, 2938
Kruize AA, 754
Kubasiewicz E, 541
Kubo M, 474, 731, 1363
Kudchodkar S, 1089
Kuffner EK, 2449
Kühn K, 1644, 2768
Kuipers JG, 931, 2679
Kuis W, 728
Kullich WC, 2940
Kuncl RW, 1954
Kunkel SL, 31
Künzler P, 1865
Kurimoto M, 275, 550
Kusaka M, 491
Kuwana M, 737, 893, 1654
Kvien TK, 2941
Kyriakidis M, 902

L

Laan RFJM, 1254, 1515, 2525
Laasonen L, 1908
Lafeber FPJG, 3, 2562
Lahdenpohja N, 176
Lahita RG, 2367
Laiho K, 241
Lally E, 653
Landes J, 1420
Landthaler M, 2665
Lane KA, 1786
Lane NE, 202
Lang A, 1819
Lang S, 2888
Langford CA, 508
Langleben D, 902
Lao L, 819
Lark MW, 128
LaRosa G, 1022, 2750
Lau CA, 693
Lauber J, 2392
Lauer S, 1713
Laufer S, 2320
Lautzenheiser RL, 1587
Lavalle C, 1331
LaValley M, 1105
Laverty S, 120
Lawford R, 2456
Lawlor KE, 442
Lawson, CA, 2932
Lawson TM, 2460
Le Goff P, 2485
Le Graverand M-PH, 1808
Le Henaff C, 2485
Le Mouel S, 2134
le Toumelin P, 666
Leaños-Miranda A, 866
Lee CH, 1707
Lee L, 2456
Lee SK, 1707
Leff RD, 2235
Lefkowith J, 1587
LeGrand A, 2078
Leirisalo-Repo M, 1209
Leite MOR, 202
Lemckert AA, 570
Lems WF, 979
Lennox RD, 1599
Lequesne M, 2539
Levarht EWN, 2029
Levin IW, 846
Levin J, 128
Lewis CE, 1540
Lewis EN, 846
Leyte A, 979
Lhote F, 666
Li H, 618
Li SC, 1966
Li Y, 1689, 2331
Liang X, 1555
Liberman UA, 202
Lichauco JJ, 1713

Licht R, 1320
Lidington EA, 138
Liew FY, 1481, 2790
Life PF, 1620, 2697
Lilien M, 728
Limbaugh BH, 2275
Lin D, 618
Lin N, 2193
Linder R, 1887
Liossis S-NC, 1114
Lipsitz S, 1370
Lipsky PE, 626, 2620, 2715
Lisignoli G, 1444, 1800
Lisse J, 981, 2797
Liu D, 1555, 2146
Liu G, 1428
Liu H, 21, 2899
Liu X, 876
Lockshin MD, 1466, 2215
Loening A, 1401
Loeuille D, 2285
Lohmander LS, 2548
Lojacono A, 1832
Long P, 608, 2311
Lonzetti LS, 735
López de Castro JA, 1677
López-Nevot MA, 307
López-Pedrera C, 2467
Losina E, 1184
Lotz M, 826, 1071, 1633, 1644, 2768
Louis-Plence P, 1281
Lovász G, 682
Lu X, 486
Lublin DM, 138
Lucas M, 1663
Luchetti M, 2653
Ludwicka-Bradley A, 1370
Lui L-Y, 2065
Lum R, 618
LUMINA Study Group, 2797
Lunt M, 1033, 1248
Luqmani RA, 912
Luta G, 1587
Luthra HS, 1504
Luu NT, 2851
Luukkainen R, 315
Luyten FP, 85, 1608, 1928
Lynch JM, 2448

M

Maccioni P, 1155
Macfarlane GJ, 940
Machner A, 956
Mack KT, 723
MacPherson BR, 1966
Maenaka K, 384
Magdalou J, 351
Magder LS, 2342, 2350
Mageed RA, 2387
Magill C, 703
Maiden N, 912
Maini RN, 245, 1215, 1968, 2055
Majeed W, 1689
Makino H, 275, 550
Maksymowych W, 931
Malfait A-M, 1215
Malice M-P, 202
Malik AS, 1215
Mallek JA, 2235
Maly FE, 2213
Manfredi AA, 2841
Manheim LM, 212
Männer G, 856
Mannik M, 1717
Manning AM, 1897
Mansoor R, 2367
Mantovani A, 2841
Manz R, 2435
Manzi S, 2338
Mapp PI, 1534
Marcus DM, 2461
Marcusson KC, 2531
Marder G, 1203
Marell J, 2435
Margules KR, 2449
Mariette X, 2458
Marinho E, 488
Marinova-Mutafchieva L, 451
Markenson JA, 1587
Märker-Hermann E, 931, 1209
Markland J, 1351
Marmé D, 2055
Marpeau C, 1143
Martel-Pelletier J, 73, 595, 1237, 2320
Martens PB, 978
Martin A, 2485
Martín J, 307
Martin RW, 653
Martin T, 490
Martin V, 1203
Martinez A, 1261
Martínez de la Escalera G, 1331
Martin-Mola E, 1261
Maruyama M, 974
Mary JY, 2485
Marzo-Ortega H, 1177, 2112
Masago R, 693
Masana L, 2761
Masgala C, 1401
Mason JC, 138
Mason RM, 1455
Mason T, 523
Mastrorosato M, 1155
Mastrovic K, 1209
Masuko-Hongo K, 838, 1056
Masutani K, 2097
Mat C, 2686
Matarán L, 307
Mateo L, 2941
Mathews J, 2633
Matsuda Y, 1525
Matsui T, 384
Matsuo S, 2425
Matteson EL, 2943
Mattey DL, 1529
Matucci-Cerinic M, 1865, 2665
Mau W, 528
Mayes M, 653, 1359
Maziéres B, 2539
Mazzon E, 2909
Mazzuca SA, 1786
McAlindon TE, 1105, 2107
McBeth J, 940
McCune WJ, 397, 912
McDonagh KT, 1230
McDonald TJ, 2836
McDougall S, 2572
McEvoy A, 782, 1761
McGonagle D, 2112
McGowan J, 2477
McGwin G Jr., 981, 2797
McIlwain HH, 202
McInnes IB, 1481
McKenna L, 1304, 2777
McLaughlin-Miley C, 1599
McMichael AJ, 2038
McMurray R, 984
McNeil HP, 2456
McNeish JD, 2922
McSweeney PA, 1848
Medsger TA Jr., 653, 1654, 1663, 2828
Meheus L, 2255
Mehta A, 486
Meine A, 2435
Meisel C, 2435
Melin J, 1229
Melo-Gomes JA, 202
Melrose J, 1428
Menage J, 2586
Mengshol JA, 1096
Menkes C-J, 202
Mentlein R, 1082
Mercier P, 535
Merconi PL, 1484
Merkel PA, 912
Merkesdal S, 528
Meroni PL, 243, 1832, 2870
Merrill JT, 1466
Messmer K, 1420
Metz CN, 1273
Metzler C, 469
Meyer CM, 513
Meyer JM, 286
Meyer O, 1736, 1965
Meyringer R, 2665
Miceli-Richard C, 1964
Michel BA, 53, 703, 956, 1865, 2665
Mielants H, 186, 2938
Migita K, 884
Mikecz K, 682, 2922
Mikkelson M, 481
Milewicz DM, 893, 1855
Miller NE, 541
Miller WH, 128
Millet V, 1444
Milner JM, 2084
Min D-J, 561
Min Y-I, 912
Minear M, 2125
Mineau F, 595
Minshall ME, 2611
Miossec P, 1293
Mita Y, 339
Mitchell RA, 1273
Mix KS, 1096
Miyawaki S, 550
Mizuno M, 2425
Mo L, 1225
Mödder U, 2492
Mogi M, 1003
Mohan N, 2862
Moldofsky H, 222
Molenaar ETH, 997
Molinaro C, 2642
Molteni R, 2870
Mönkkönen H, 2201
Mönkkönen J, 1908, 2201
Monson NL, 2620
Montgomery H, 196
Moody M, 693
Moore GF, 2235
Moos V, 2213
Morand EF, 1273
Morant S, 1587
Morel JCM, 1568
Moreland L, 653, 1977, 1984
Morgan BP, 2425
Mori Y, 2512
Moriguchi M, 1266
Morimoto C, 296
Morita Y, 275
Morris S, 389
Moser KL, 1122, 2807
Moskowitz RW, 1471
Mountz JD, 964, 1555, 2146
Moutsopoulos HM, 408, 490, 902
Moxley G, 286
Mraz-Gernhard SM, 2111
Mu JY, 1428
Mulcahy E, 2107
Müller A, 469
Müller B, 2213
Müller-Ladner U, 964, 1865, 2665
Müller-Steinbach S, 761
Multiple Outcomes of Raloxifene Evaluation Study, 2611
Muñoz-Gómez J, 66
Murasawa A, 339
Murphey JJ, 1917
Murphy AGV, 1993
Murphy EP, 782, 1761
Murray CW, 1470
Muscarà M, 1832
Mwale F, 120
Myers LK, 1775

N

Nadiv O, 2176
Nagaraju K, 2376
Naides SJ, 1582
Nakajima T, 1013, 1545
Nakamura H, 838, 1013, 1056, 1545
Nakano M, 339
Nakashima H, 2097
Nakashima T, 884
Nakazawa M, 1013, 1545
Nakazono K, 339
Nakken B, 638
Nambiar MP, 1114, 1336
Nanchahal J, 1754

Nash GB, 2851
Natt RS, 2728
Nawrath M, 1865
Neas BR, 1122
Negishi M, 2512
Neidhart M, 1865
Nejentsev S, 315
Nelson AM, 523
Nelson JL, 1848
Nèmcová D, 2387
Netter P, 351, 2285
Neumann W, 956
Neupert W, 1698
Neureiter D, 1304
Nevitt MC, 202, 811, 2065
Newby AC, 2888
Ng S, 361
Ngai N, 1689
Nguyen M, 2539
Niccoli L, 1155, 2933
Niederlová J, 2387
Nietert PJ, 2705
Nieto A, 307
Nieuwenhuizen MG, 1254
Nieva DRC, 1582
Niitsu Y, 2160
Niles JL, 912
Ninomiya T, 2097
Nishi T, 296
Nishikawa K, 2425
Nishikawa M, 96
Nishikawa T, 1003
Nishioka K, 384, 838, 1013, 1056, 1545
Noël D, 1444
Nolla JM, 2941
Notarnicola C, 163
Noyszewski EA, 1089

O

Oakley SP, 2138
Oana S, 2211
Oates J, 2633
Oates JC, 1230
Ochs RL, 826
O'Connor P, 2112, 2932
O'Dell JR, 2235
Odendahl M, 2620
O'Donnell K, 442
O'Driscoll BR, 243
O'Fallon WM, 523
Ogawa A, 2211
Oguchi T, 2503
O'Hanlon D, 1351
Ohmoto Y, 275
Ohta M, 974
Okada H, 2425
Okada N, 2425
Okamoto T, 2160
Ólafsdóttir G, 2548
Olee T, 826, 1633, 2768
Oliverio PJ, 2862
Olivier P, 2285
Olivieri I, 180, 1155, 2933
Ollier WER, 61, 239, 802, 1529, 1782, 2358, 2387, 2693
Olsen N, 1984
Olson JL, 618
Olson JM, 2807
Olszewski WL, 541
Onuma H, 1056
Oppers-Walgreen B, 1320
Orchard TR, 2728
Orfanos SE, 902
Origuchi T, 884
Orldandini G, 2653
Ostendorf B, 2492
Østergaard M, 2018
Ostrov BE, 240
O'Sullivan JJ, 1660
Otsuka M, 384
Otsuka T, 2097
Otsuki T, 491
Otterness IG, 2922
Otto JM, 682
Ouzzine M, 351
Overbeek M, 1897
Ozaki Y, 419
Ozawa T, 974
Ozen S, 2387
Özyazgan Y, 2686

P

Pablos JL, 1382, 1667
Padreño J, 2761
Padula A, 1155, 2933
Page J, 2477
Pagliari LJ, 21
Paikos S, 408
Paleolog EM, 245, 2055
Palmer JT, 703
Palmer WR, 2235
Pálsdottir E, 2548
Pan Z-J, 737
Panaritis C, 2331
Panayi GS, 1993
Pandey JP, 2705
Pandya-Lipman RK, 1775
Pap G, 956
Pap T, 676, 956, 1865, 2665
Papworth J, 2697
Paredes S, 2761
Parenti D, 1470
Park CC, 1022, 1568
Park DC, 2125
Park DS, 979
Park S-H, 561
Park W, 561
Park YB, 1707
Paroncini P, 2653
Pascual M, 307
Pascual-Salcedo D, 1261
Pasker-de Jong PCM, 1254
Pasquali J-L, 490
Pasternak A, 176
Paton TW, 231
Paulsen GA, 2235
Pazdur J, 541
Peck AB, 693
Peene I, 2255
Pelletier J-P, 73, 595, 1237, 2320
Pennec Y, 2485
Pepper L, 802
Perdriger A, 535
Peretz A, 2943
Peri G, 2841
Perides G, 1401
Perlman H, 21, 2899
Pertovaara M, 176
Peters JH, 2572
Peters R, 2492
Petersen EJ, 754
Petersen W, 1082
Peterson J, 2477
Peterson MGE, 361
Petri M, 389, 2342, 2350
Pettit AR, 105
Pettitt DJ, 1170
Pfueller B, 1962
Piacentini A, 1800
Picot M-C, 163
Piecyk M, 2879
Pierangeli SS, 876
Piesco NP, 608
Pieterman E, 48, 570
Piette J-C, 488, 1836, 2118, 2402
Pillemer S, 1170
Pincus T, 1234, 1587
Pinet V, 1281
Pisetsky DS, 1, 1043, 1722, 2078, 2448
Pisoni MP, 1832
Plant T, 921
Plater-Zyberk C, 2697
Plotz PH, 389, 1975
Pluta AF, 389
Polihronis M, 408
Ponath P, 1022, 2750
Poole AR, 120, 2503
Pope JE, 1351, 1841
Pope RM, 21, 1022, 2750, 2899
Porepa M, 1768
Pöschl E, 1943
Postlethwaite AE, 1775
Potter K, 846
Poubelle PEE, 202
Poulton KV, 1529
Povey A, 662, 2706
Praderio L, 2841
Praprotnik S, 1484
Pratta MA, 1401
Preijers F, 754
Price PA, 826
Pricop L, 739
Priem S, 151
Pritzker K, 1071
Proudman S, 1177
Pruss A, 626
Psevdi E, 902
Pufe T, 1082
Pulkkinen L, 481
Punaman C, 1713
Putschky N, 2679
Putz R, 2556

Q

Qin M, 2065
Qin S, 1022, 2750
Quach J, 2768
Quinn, MA, 2932

R

Radda I, 266
Radford D, 921, 2851
Radke S, 331
Rahmouni A, 2134
Ralston SH, 2185, 2790
Ramal L, 307
Ramey DR, 2746
Ramos M, 1677
Ramroth D, 2477
Ramsey-Goldman R, 2338
Ranger P, 73, 595
Rao S, 2807
Raschi E, 2870
Rasnik D, 703
Rattner JB, 1808
Rattner JP, 1808
Ray D, 397, 2358
Ray NB, 1582
Ray RB, 1555
Raymackers J, 761
Raymond Y, 735
Raynauld J-P, 735
Reboul P, 73, 2320
Reddig J, 2936
Reddy R, 1089
Redlich K, 266
Reece R, 2024
Reed AM, 1775
Reeves WH, 2367
Refior HJ, 1420
Reicin A, 1229
Reid DM, 2790
Reifert J, 772
Reiff A, 1411
Reinhold-Keller E, 1887
Reiser M, 2072, 2556
Reiter K, 626, 2620
Renou C, 2118
Reparon-Schuijt CC, 41, 2029
Rethage J, 1865
Reusch P, 2055
Reuss E, 1209
Reveille JD, 361, 981, 1359, 2446, 2797
Reviron D, 535
Rheinheimer C, 2392
Ricciardi DD, 169
Rich E, 735
Richards HB, 2367
Richardson BC, 397
Richardson JB, 2586
Richert JR, 2862
Richette P, 2134
Riebman JB, 2111
Riemekasten G, 2435
Rijke TPM, 1320
Rijkers GT, 728
Rinnert T, 956
Ritter T, 1943
Rittig M, 151
Rivero M, 1382, 1667
Roberts DJ, 1848
Roberts S, 2586
Roberts-Thomson PJ, 245, 343
Robinson WH, 1977

Rodriguez-Portales JA, 202
Rogers MJ, 2201
Roivainen A, 2705
Roizenblatt S, 222
Roman MJ, 2215
Romme TC, 1515
Rood MJ, 1515
Roschke V, 1313
Rose RJ, 481
Roseman J, 2797
Rosen A, 389, 2376
Rosengren B, 2761
Rosenthal E, 242, 2118
Rosloniec EF, 2413
Rottman JB, 1022, 2750
Roudier J, 535
Roussin A, 735
Roussos C, 902
Roux S, 2458
Rovere Querini P, 2841
Rowan AD, 1620, 2296
Rozman B, 1484
Rubini F, 1155
Rubio A, 1261
Růžičková S, 2387
Rullas J, 1382
Ruof J, 528
Rupprecht HD, 1698
Russell AS, 2728
Russell KA, 463
Russo RAG, 1139
Ruth JH, 1022, 1568, 2750
Rutter J, 2296

S

Sa S, 703
Saag KG, 202
Säämänen A-M, 947
Sabbadini MG, 2841
Sadeghi S, 1411
Sahly H, 931
Said-Nahal R, 1964
Saito K, 2879
Saito N, 339
Saito S, 1003
Sakaguchi H, 491
Sakamaki S, 2160
Sakata M, 838, 1056
Saleem G, 1966
Salminen H, 947
Salminen JJ, 481
Salmon I, 2371
Salmon JE, 361, 739, 876, 1225, 2215
Salmon M, 2633
Salter DM, 1795
Salvarani C, 1155, 2933
Salvemini D, 2909
Sambo P, 2653
Sammaritano L, 1466
Sampey AV, 1273
Sandberg G, 2862
Sanders EAM, 728
Sanmartí R, 66, 1387
Santiago B, 1382, 1667
Sany J, 1444, 1736
Saraux A, 2485
Sarkar S, 128
Sarma AVS, 1089
Sartipy P, 2761
Sasaki K, 296, 2160
Sato EF, 96
Sato T, 2160, 2193
Sato Y, 2160
Satoh K, 260
Satoh M, 2367
Savage COS, 921, 2851
Say S, 956
Scheel-Toellner D, 2633
Scheinberg MA, 492
Scheinecker C, 856
Schellekens GA, 41
Scherer A, 2492
Schett G, 266, 2888
Schiff M, 1984
Schmaier AH, 1230
Schmid BJ, 2888
Schmitt WH, 1887
Schnarr S, 2679
Schneider H, 1943
Schneider M, 2492
Schnitzer TJ, 202, 1587
Schöffski O, 528
Schölmerich J, 2665
Schulitz K-P, 2492
Schumacher HR, 1689
Schumann F, 761
Schwartz T, 1587
Schwarzberg H, 956
Sciore P, 1808
Scola MP, 794
Scott CG, 1504
Scott DGI, 323, 1248
Scott DL, 1993
Scott-Lennox JA, 1599
Sebbag M, 2255
Seeman E, 202
Seftor EA, 1582
Seibold JR, 653, 1351
Sekimata M, 260
Seldin MF, 618
Seligman VA, 618
Selzer E, 266
Semana G, 535
Sems KM, 2235
Sen M, 772
Senécal J-L, 735, 2331
Şenocak M, 2686
Serraino I, 2909
Serre G, 2255
Sestak AL, 1122
Seta N, 931
Severens JL, 1515
Sexton DJ, 1043
Shadick N, 1048
Shaham B, 1411
Shamiyeh E, 2899
Sharma S, 1998
Sharp JT, 202, 1984
Shaw M, 2367
Shea B, 1841, 2477
Shelley E, 802, 1782
Shen W, 2611
Shibatomi K, 884
Shigemitsu HH, 1713
Shikhman A, 2768
Shima M, 2211
Shinawi M, 1416
Shingleton WD, 1620, 2296
Shiozawa F, 2512
Shiwen X, 712
Shlopov BV, 1775
Shnier R, 2138
Shoenfeld Y, 1484
Sibilia J, 1736
Sibley J, 1351
Sideras P, 408
Siebert S, 2460
Siegel JN, 2862
Sieper J, 2936
Sierakowski S, 1865
Sievers ML, 1170
Sigal LH, 2463
Silman AJ, 61, 239, 323, 662, 940, 1033, 1248, 2693, 2706
Silver RM, 1370, 2705
Silverman SL, 2611
Siminoski KG, 202
Simon LS, 1473
Singh G, 2746
Singh RR, 432
Sipola E, 2705
Slaper-Cortenbach ICM, 728
Smale S, 2728
Smith CD, 1351
Smith GN Jr., 1473
Smith M, 1998
Smith MD, 105, 245, 343
Smolen JS, 266, 856, 1721, 2218, 2888
Soini I, 241
Sokka T, 515, 1234, 1587
Solé M, 66
Solovieva SA, 1908
Song GG, 2146
Song J, 212, 1707
Song YW, 931
Sonneborn D, 1160
Sont JK, 754
Spaull J, 2697
Spaull JR, 1620
Specks U, 463, 912, 2836
Spencer DR, 703
Spencer RGS, 846
Sperling R, 1229
Spiera RF, 912
Spiller OB, 2425
Sporn MB, 1096
Srivatsa B, 2944
Stafford HA, 737
Staines N, 1917, 1993
Stanke-Labesque F, 1143
Stastny P, 1775
St.Clair EW, 912, 1043, 1231
Steen V, 653, 2828
Steere AC, 1401
Stefánsson K, 2247, 2548
Stefánsson SE, 2548
Steiner CW, 266
Steiner G, 266, 578, 1721, 2218, 2888
Steinfeld SD, 2371
Steinsson K, 2247
Stern MP, 2737
Stevens A, 2358
Stevens CR, 1534
Stohl W, 1313
Stone JH, 912, 1149
Stoop R, 2922
Stopford A, 802
Stout A, 1411
Stout T, 1411
Stradmann-Bellinghausen B, 1209
Stramba-Badiale M, 243, 1832
Strandberg C, 2018
Stratigis N, 902
Straub RH, 493
Strieter RM, 31
Strober S, 1525
Stroup GB, 128
Stuchin S, 578
Stucki G, 53
Stummvoll GH, 266
Suarez Charlyn, 618
Suarez-Almazor ME, 2461
Suda T, 1003
Sugiyama E, 974
Suh CH, 1707
Sumida T, 1127
Suri N, 1455
Swift BA, 128
Swinkels HL, 2009
Symmons DPM, 323, 1033, 1248, 1998
Szkudlarek M, 2018

T

Tajima K, 419
Tak PP, 1897
Takahashi K, 1003
Takahashi M, 2160
Takahashi N, 1003
Takai M, 1545
Takei S, 1411
Takemura S, 13
Takeuchi HT, 2512
Takeuchi T, 550
Taki H, 974
Talal N, 693
Tamaki K, 474, 731, 1363
Tan FK, 893, 981, 1855, 2446
Tanaka H, 296
Tanaka M, 2160
Tanaka S, 491
Taniai M, 275, 550
Taniguchi M, 1127
Tanimoto T, 275, 550
Tardif G, 73
Tavoni A, 245
Taylor PC, 245, 2055
TeKoppele JM, 2562
Tennant B, 486
Teodorescu M, 376
Terai C, 1266
Terai M, 2211
Terajima H, 1716
Terkeltaub R, 1071

Terlain B, 351
Testoni C, 2870
Tetlow LC, 585
Tew MB, 981, 2446
Thibault V, 2118
Thomas R, 105
Thomas S, 1993
Thompson AE, 1841
Thompson JW, 1775
Thompson S, 2697
Thomson BM, 1795
Thomson W, 802, 1529, 1782, 2358
Thorel JB, 2485
Thorleifsson G, 2247
Thorsteinsson J, 2247
Tiberghien P, 535
Tidow F, 2392
Tillmann B, 1082
Tincani A, 1832, 2870
Togari A, 1003
Tohidast-Akrad M, 266, 2888
Toivanen A, 315
Toivanen P, 2705
Tokumoto M, 2097
Tomatsu T, 1003
Tomita M, 96
Tomokuni A, 491
Toneguzzi S, 1800
Torbergsen AC, 2185
Touitou I, 163
Tourkina E, 1370
Toussirot E, 535
Townend JN, 2707
Trabandt A, 469
Tremoli E, 2870
Tries S, 2320
Troeberg L, 1754
Trupin L, 1160
Tsao BP, 432
Tsokos GC, 1114, 1336
Tsuda E, 1003
Tsujihata M, 884
Tsuruha J-I, 838, 1056
Tsuruya K, 2097
Tufik S, 222
Tugwell P, 2477
Tuokko J, 315
Turesson C, 1170
Türk B, 2888
Tüzün Y, 2686
Tylzanowski P, 1928
Tzioufas AG, 408, 490

U

Udagawa N, 1003
Uehira K, 419
Ueki A, 491
Uemura Y, 419
Uesato M, 1266
Uhlfelder ML, 912, 1149
Uhrin Z, 1525
Ungethüm U, 761
Union A, 761, 2255
Urbano-Márquez A, 1387
Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group, 1984
Uysal Ö, 2686

V

Vail TP, 2078
Valbracht J, 2768
Valdéz JC, 682
Valente RM, 912
Valerio D, 48
Valls I, 2485
Valls-Solé J, 1387
Vallve JC, 2761
Valsson J, 2247
van Bruggen MCJ, 1320
van Damme N, 186
van de Geest DA, 1897
van de Laar MAFJ, 1515
van de Loo FAJ, 2413
van de Putte LBA, 754, 1515, 2525
van de Stadt RJ, 979
van den Berg WB, 2413
van den Bosch F, 186, 2938
van den Hoogen FHJ, 754
van Denderen CJ, 1515
van der Heijde D, 180, 1876
van der Horst-Bruinsma IE, 1396, 1476, 1965
van der Linden S, 1052, 2242
van der Vliet-Hristova M, 2572
van der Wilt G-J, 1515
van Ede AE, 1515, 2525
van Esch WJE, 41, 2029
van Gestel AM, 1719, 2009
van Kooten C, 41, 2029
van Laar JM, 754
van Mierlo GJ, 997
van Riel PLCM, 1254, 1719, 2009
van Roon JAG, 3
van 't Hof RJ, 2185, 2790
van Venrooij WJ, 41
Varga J, 376, 653
Veale DJ, 2024
Veihelmann A, 1420
Velasco F, 2467
Velins S, 682
Vencovský J, 2387
Verburg RJ, 754
Verhoeven AC, 1052, 2242
Vermes C, 682
Vernallis AB, 1620
Versijl N, 2562
Verweij CL, 41, 2029
Vescovi F, 1832
Veys EM, 186, 931, 2255, 2938
Vignati G, 1832
Vignon E, 1808, 2539
Vikingsson A, 2247
Vilei EM, 1819
Vincenti MP, 1096
Vlachoyiannopoulos PG, 902
Vogels R, 48
Voisin M-C, 2134
Volin MV, 31, 1568
Vollmer-Conna U, 343
von der Mark K, 1943
Voskuyl AE, 997
Voulgarelis M, 490
Vuorio E, 947

W

Wagner JL, 1504
Wagner K, 1943
Wakefield RJ, 1177, 2932
Waldmann H, 1998
Wallis DD, 1855
Walsh DA, 1534
Walter F, 2285
Walters GB, 2548
Walther M, 331
Walton RC, 1775
Wang BWE, 1525
Wang GF, 1689
Wang J, 2367
Wang N, 893
Wang X, 1587
Wang Y, 1555
Wang Z, 1689
Ward MM, 1467, 1728, 2711
Waris E, 1908
Warke VG, 1336
Warner AE, 1959
Warrington KJ, 13
Watrin A, 2285
Weaver A, 1587, 1984
Weber M, 1965
Wedekind F, 2492
Wees SJ, 2235
Wei X-Q, 2790
Weider S, 1698
Weinberg JB, 2078
Weiner SR, 653
Weinstein A, 653
Weiß C, 2435
Weisman M, 653
Welch V, 1841, 2477
Wells G, 2477
Welsing PMJ, 2009
Wendling D, 535
Wenting-Van Wijk MJG, 2562
Westgeest TAA, 1515
Westhovens R, 202
Westman P, 1209
Weyand CM, 13
White B, 653
Whittington KB, 2413
Wicks IP, 442, 985
Wiedemann A, 1281
Wigley FM, 389, 653, 912, 1954
Wiklund O, 2761
Wiles NJ, 323, 1033
Wilkinson WE, 1043
Williams BD, 2460
Williams EN, 811
Williams K, 2737
Williams RO, 451, 1215
Willis A, 486
Wilson A, 1587
Winfield JB, 751
Wing J, 202
Wintersberger W, 2146
Wofsy D, 1730
Wolbart K, 1962
Wolfe F, 1234, 1587
Wolkenstein P, 2134
Wollenhaupt J, 2679
Wong HK, 1336
Wong JB, 2746
Wong WK, 432, 653
Wood M, 662, 2706
Woodruff DC, 31, 1568
Woods JM, 31, 1568
Woolley DE, 585
Worthington J, 61, 239, 2358, 2693
Wright TM, 1654
Wroblewski K, 1089
Wu L, 442, 1022, 2750
Wu X, 2275, 2642
Wulfraat NM, 728

X

Xanthou G, 408
Xie J, 2146
Xie JF, 1555
Xie S, 2611
Xu L, 2065
Xu Q, 2888

Y

Yabe T, 384
Yajima N, 2512
Yamamoto K, 384
Yamamoto S, 2211
Yamamura M, 275, 550
Yamane K, 474, 731, 1363
Yamano Y, 96
Yamasaki S, 884
Yamashita N, 974
Yamashita T, 419
Yamauchi H, 275, 550
Yamauchi N, 2160
Yan C, 1599
Yang H, 2038
Yang J, 397
Yang PA, 1555, 2146
Yang YH, 111, 2459
Yano K, 1003
Yanover MJ, 202
Yarwood H, 138
Yasuda T, 120
Yazawa N, 1363
Yazici H, 2686
Yazici Y, 169, 1466
Yelin E, 1160, 1194
Yli-Jama T, 2705
Yoshida K, 339
Yoshida M, 2572
Yoshino S, 1545
Youinou P, 2485
Youn J, 561
Young L, 343
Young N, 1768
Youssef PP, 245, 343, 1744
Yu DTY, 931
Yu W, 2065
Yuan G-H, 1056
Yurdakul S, 2686

Z

Zacher J, 151
Zaleska M, 541
Zanders E, 2697
Zanelli E, 307
Zehntner S, 105
Zeidler H, 180, 528, 2679
Zeiler G, 1304
Zelazko M, 1139
Zhang H, 1689
Zhang H-G, 964, 1555, 2146
Zhang J, 682
Zhang Y, 2065
Zhang Z, 397, 712, 2275
Zhen D-K, 1848
Zheng B, 712, 1438
Zhou T, 2146
Zhu F, 2705
Zien A, 2777
Zini N, 1800
Zinsmeister AR, 1504
Zuluaga FJ, 693
Zuñiga R, 361
Zwölfer B, 856

SUBJECT INDEX

Arthritis & Rheumatism, Volume 44, Numbers 1–12, 2001

A

α-fodrin, cleavage by granzyme B, 2376
$\alpha_v\beta_3$ antagonist, SB 273005 in rat adjuvant-induced arthritis, 128
Abdominal subcutaneous fat aspiration, amyloid fat deposits in RA, 66
Acetaminophen, for OA
  in alcoholic patients, 2449
  in patients with liver disease, 2448
  vs. diclofenac plus misoprostol, 1587
Activator protein 1, synergistic induction of MMP-1 by IL-1α and oncostatin M in, 2296
Activity limitations, in older adults with arthritis, 212
Activity loss, onset of depressive symptoms and, 1194
Acupuncture, for OA of knee, 819
Acute inflammatory arthritis, mediators of IL-1-dependent, 442
ADAM15. *See* Metargidin
Adenovirus
  Ad5.fib16 vectors for gene transfer to synovium, 570
  mediation of gene transfer to synovial fluid and, 48
  overexpression of TIMP-1 reduces tissue damage in mice, 2888
Adjuvant-induced arthritis
  Bcl-2 and FLIP, differential expression pattern in, 2899
  cysteine protease activity up-regulation in ankle joints, 703
  fractalkine, in RA and in rat models, 1568
  SB 273005, disease-modifying activity of, 128
  selectins and, 1428
Adult-onset Still's disease. *See* Still's disease
African American population, SLE in
  anti-Ku autoantibodies in, 2367
  glutathione S-transferase null alleles and, 981
  predictors of damage in LUMINA cohort, 2797
Aggrecanase
  MMPs in Lyme arthritis, 1401
  OA lesions and, 1455
Aging
  arthritis prevalence and activity limitations in older adults, 212
  knee joint cartilage morphology and deformation, 2556
  normal, apoptotic cell death not widespread in, 1304
  structural modifications of bovine articular cartilage, 2285
  susceptibility of cartilage to MMP-mediated degradation, 2562
Akt, protein kinase, regulation of TNFα-mediated apoptosis of RA synovial fibroblasts, 1555
Alendronate, in patients receiving glucocorticoids, 202
Allopurinol, desensitization to, following cutaneous reactions, 231
American College of Rheumatology (ACR)
  Bone and Joint Decade, 1969
  glucocorticoid-induced osteoporosis, recommendations for prevention and treatment of, 1496
  new directions for 2001 journals, 1
  OA, recommendations for management, critiques, 2448, 2451, 2455
  OA, treatment with acetaminophen in alcoholic patients, 2449
  OA, treatment with acetaminophen in patients with liver disease, 2448
  presidential address, 247
  RA, 1987 criteria, 2485
  RA, improvement criteria, 1052, 1719, 1720
  2000 Slide Competition winners, 513
  SSc classification criteria, preliminary, 735
Amyloid myopathy, case study, 1954
Amyloidosis
  clinical significance in RA, 66
  risk of type AA, secondary to RA, 1266
Anemia, in RA, ferritin and serum transferrin receptor as predictors of iron deficiency, 979
Angiogenesis
  decay-accelerating factor expression in, 138
  JRA, correlation with revascularization of human synovium engrafted into SCID mice, 794
  regulation by IL-8 and epithelial neutrophil activating peptide 78 in rheumatoid joint, 31
Animal models. *See names of specific animals*
Ankle, cysteine protease activity up-regulation in adjuvant-induced arthritis, 703
Ankylosing spondylitis (AS)
  anti-TNFα therapy, effects on synovium in, 186, 2937, 2938
  Brucella infection in, 2939
  celecoxib for, 180
  criteria for clinically important improvement, 1728
  hormone levels and birth order, 1476
  improvement criteria, 1728, 1876
  infliximab for severe disease, 2936
  risk of in first-born children, 1964, 1965
  severity, determinants of, 1396
  silicone breast implants and, 2477
  thalidomide in severe refractory seronegative spondylarthropathy, 2456, 2457
Antiapoptotic proteins, Bcl-2 and FLIP in experimental arthritis, 2899
Anti-β_2-glycoprotein I, statin inhibition of endothelial activation mediated by, 2870
Antibiotics, intravenous doxycycline therapy for RA, 1043
Antibodies/autoantibodies. *See names of specific antibodies*
Anti-CD20 chimeric monoclonal antibodies, for WG, 2836
Anti-citrulline-containing peptide antibody, secretion by B lymphocytes in RA synovial fluid, 41
Anti-DNA-based peptide, in murine lupus, 432
Anti-double-stranded DNA (anti-dsDNA)
  antibodies, following infliximab therapy for RA, 1966
  SLE, decreased level associated with SLE flare, 2342
  $SmD1^{83\text{-}119}$ peptide accelerates murine lupus, 2435
Anti-endothelial cell antibodies (AECA), micro- and macrovascular, 1484
Antigen-induced arthritis
  early degradation of types IX and II collagen in, 120
  intraarticular liposomal clodronate in, 1908
  murine, inducible NOS deficiency in, 1420
Anti-KIR autoantibodies, in Behçet's disease, 384
Anti-Ku autoantibodies, in SLE, 2367
Antineutrophil cytoplasmic antibodies (ANCA)
  monocytic oxygen radical release induced by, in vitro, 1698
  myeloperoxidase and proteinase-3, to activate PMN cells in WG and microscopic polyangiitis, 921
  pro-PR3-reactive, and disease activity in WG and microscopic polyangiitis, 463
  promotion of migration of neutrophils through endothelium by, 2851
Antiphospholipid syndrome (APS)
  COX-2 inhibition and thrombosis, 984
  ICAM-1 and pregnancy loss, 1225
  intravenous immunoglobulin, amelioration mechanism, 876
  lupus band test yields negative results in, 488
  Sapporo criteria for, 1965
  thrombosis, high rate after fetal loss in, 1466
  tissue factor in, 246
Anti-Ro antibodies, heart rate-corrected QT interval in children of anti-Ro-positive mothers, 242, 243

Anti-Ro/SSA antibodies, congenital heart block and, 1723, 1832
Anti-topoisomerase I antibodies
HLA-DQβ1 domain and, 491
in SLE, 376
in SSc, 737
Anti-tumor necrosis factor α (anti-TNFα)
ATTRACT trial, paradox of beneficial treatment effects in responders in, 2703
effects on synovium in spondylarthropathy, 186, 2937, 2938
Anti-U1 RNP antibodies, ordering of human response to, 368
Apoptosis
anti-Fas-induced, reduced by hyaluronan, 1800
autoantigen proteolysis in secondary necrosis, 2642
Bcl-2 and FLIP in experimental arthritis, 2899
CD95 signaling in human chondrocytes, 1644
chondrocyte, 1237
defective Fas ligand-mediated apoptosis predisposes to arthritis after *Mycoplasma pulmonis* infection, 2146
inducible NOS pathway and inflammation-induced osteoporosis, 2790
MMP-9 and vascular morphology in early arthritis and, 2024
in normal aging and osteoarthritic human knee cartilage, 1304
protein kinase Akt to regulate TNFα-mediated apoptosis of RA synovial fibroblasts, 1555
RA, Fas-mediated, in synovial macrophages, 21
SS, caspase 3 and Bax expression in, 693
SSc, fibroblasts, decreased in, 1667
Artificial neural network, differentiation between WG and Churg-Strauss syndrome by, 1887
Aseptic prosthesis loosening, rat model, 956
Aspirin, as treatment for high thrombosis rate after fetal loss in APS, 1466
Atherosclerosis, SLE and, 2215, 2331
Atrial septostomy, for SSc-associated pulmonary hypertension, 1660
ATTRACT trial, beneficial treatment effects in responders in, 2703
Autoantibodies. *See names of specific autoantibodies*
Autoantigens, proteolysis in secondary necrosis, 2642
Autoimmune thrombocytopenia, SLE-induced, treatment with recombinant human IL-11, 170
Autoimmunity
Fcγ receptors for immunoglobulin G, 739
NKT cells and, 1127
RA and, 2218
Autologous chondrocyte implantation, cartilage repair and, 2586
Autologous stem cell transplantation
in RA, 754
for refractory childhood SLE, 728

B

B cell-attracting chemokine (CXCL13) in SS, 2633
B cells
anti-citrulline-containing peptide antibody-producing, in RA synovial fluid, 41
BiP overexpression in RA, 761
CD20+,CD38- B lymphocyte response in RA synovium, 2029
monoclonal expansion of in SS, 490
B lymphocyte
CD20+,CD38-, response in RA synovium, 2029
oligoclonal B lymphocyte expansion in synovium in Behçet's disease, 1707
stimulator, elevated levels in systemic immune-based rheumatic disease, 1313
Bacteria. *See names of specific bacteria*
Bax, expression in mouse models, 693
Bcl-2, in experimental arthritis, differential expression pattern from FLIP, 2899
Behçet's disease
anti-KIR autoantibodies in, 384
colchicine for, 2686
linkage of HLA-B locus in, 239
mapping novel locus to chromosome 6p22-23, 2693
oligoclonal B lymphocyte expansion in synovium, 1707
Binding protein TIA-1, TNFα regulation by in macrophages, 2879
BiP, overexpression in RA, 761
Birmingham Vasculitis Activity Score, for WG, 912
Birth order
AS, hormone levels and, 1476
AS, risk of in first-born children, 1964, 1965
Bisphosphonates
clodronate, mechanism of action in vivo, 2201
intraarticular liposomal clodronate, treatment of antigen-induced arthritis, 1908
Blastomycosis-induced arthritis, 492
Bone and Joint Decade, 1969
Bone loss, inhibition by HCT1026, 2185
Bone metabolism, osteoprotegerin and receptor activator of nuclear factor κB ligand (RANKL) in RA, 253
Bone mineral density (BMD)
alendronate in patients receiving glucocorticoids, 202
change in, during early RA, 1254
IL-6 gene polymorphism and bone resorption, 196
in men with RA, 2941
osteoporosis and cardiovascular disease associated in women with SLE, 2338
strength training in early RA, 515
Bone resorption
inhibition by HCT1026, 2185
RA, combination of TNFα blockade with IL-1 and IL-17 blockade for, 1293
Borrelia burgdorferi
DNA, in synovial fluid of early undifferentiated oligoarthritis, 2679
Lyme arthritis, in vitro model of, 151
MMPs in Lyme arthritis, 1401
synovial fluid-PCR detection of pathogens, 2463
Bovine models
clusterin at surface of articular cartilage, 1795
structure of articular cartilage, MRI and age-related changes, 2285
Breast implants, silicone, rheumatologic disorders and, 2477
Brucella spondylitis, 2939
Bursitis, inflamed shoulder structures in polymyalgia rheumatica with normal ESR, 1155

C

C1 inhibitor deficiency, SLE and, 1836
C1q column, immunoadsorption with, SLE treatment, 1962
Calcium-channel blockers, for Raynaud's phenomenon in SSc, 1841
CAMPATH-1H, therapy-induced lymphopenia in RA, 1998
Cardiovascular disease
arthritis as predictor of associated death, 1170
atherosclerosis, in SLE, 2215, 2331, 2338
events in RA explained by cardiac risk factors, 2737
lipoprotein markers in RA and, 2761
mortality, role of rheumatic disease in, 2707
SLE, osteoporosis association in, 2338
Carpal tunnel surgery, predictors of outcome, 1184
Cartilage
age-related decrease in susceptibility, to MMP-mediated degradation, 2562
antisense inhibition of CD44 exon 19, 2599
apoptosis, in normal and OA cartilage, 1304
autologous chondrocyte implantation, 2586
chondrogenic potential and phenotypic stability of periosteal cells, 85

Cartilage *(cont'd)*
clusterin at surface of bovine articular, 1795
cyclic tensile strain inhibits TNFα-induced genes in articular chondrocytes, 2311
degradation of types IX and II collagen in experimental inflammatory arthritis, 120
degradation, RANTES in, 1633
degradation, synergistic effects of IL-6 and IL-1 on, 1620
Fourier transform infrared spectral imaging of, 846
glucosamine uptake in explants, 1089
intermediate layer protein, role in OA and RA, 838
matrix protein, relapsing polychondritis, matrilin 1 antibodies in, 2402
molecular markers of stable chondrocytes, 1608
morphology and deformation changes in knee, age-related, 2556
NO, effects on mitochondrial respiration in, 96
OA, C-C chemokines and receptors in, 1056
OA, cathepsin B in, and cultured chondrocytes, 1819
OA, expression pattern analysis in using complementary DNA-array technology, 277
OA, hepatocyte growth factor induction of collagenase 3 production in, 73
OA, MMP and proinflammatory cytokine production by chondrocytes in, 585
OA, MRI assessment of cartilage loss in severe disease, 2072
OA, plasma cell membrane glycoprotein 1 in knee meniscal cartilage matrix calcification, 1071
OA, regulation of NO and prostaglandin E_2 by osteopontin, 578
OA, Sox9 and type IIA procollagen in murine model, 947
OA, $VEGF_{121}$ and $VEGF_{189}$ expression in, 1082
osteoprotegerin receptor activator of RANKL, 2768
procollagenase activation in cartilage breakdown, 2084
RA, cartilage turnover and inflammation in joints, 2503
regulation of synovial fibroblast invasion by p53, 676
relapsing polychondritis, matrilin 1 antibodies in, 2402
relapsing polychondritis, orbital mucosa-associated lymphoid tissue-type lymphoma associated with, 1713
structural evaluation of, MRI and structural modifications of, 2285
YKL-40 production by articular chondrocytes, regulation of, 826
Caspase 3, expression of, in SS, 693
Caspases 3, 8, and 9, CD95-induced apoptosis in human chondrocytes and, 1644
Cathepsin
B, in OA cartilage and cultured chondrocytes, 1819
protease gene expression and joint erosion in early RA, 1744
Caucasian population
lupus nephritis, Fcγ receptor IIIA-158F allele as risk factor for, 618
RA, TNFRII polymorphism and, 61
SLE, glutathione S-transferase null alleles and, 981
SLE, predictors of damage in LUMINA cohort, 2797
CD4+,CD28- T cells, in RA, 13
CD8+,CD8+ T cells in inflammatory arthritis joints, 2038
CD20+,CD38- B lymphocytes, in RA synovium, 2029
CD44
antiapoptotic effect of hyaluronan, 1800
antisense inhibition of CD44 exon 19, 2599
deficient, DBA/1 mice, resistance to collagen-induced arthritis, 2922
CD54, antiapoptotic effect of hyaluronan, 1800
CD59, collagen-induced arthritis and, rat model, 2425
CD95, apoptosis induced by in human chondrocytes, 1644
Celecoxib, for AS, 180
Chemokine receptors
OA, C-C chemokines and receptors and, 1056
RA, expression on monocytes, 1022
RA, lymphocyte chemokine receptor expression in RA joint, 2750
Chemokines
B cell-attracting chemokine (CXCL13) in SS, 2633
Chemokines *(cont'd)*
cartilage degradation, role of RANTES in, 1633
fractalkine in rat models of, RA and antigen-induced arthritis, 1568
OA, C-C chemokines and receptors and, 1056
RA, IL-8 and epithelial neutrophil activating peptide 78, angiogenesis regulation by in joints, 31
RA, lymph draining from foot joints and, 541
SS, "lymphoid" chemokine mRNA expression in, 408
SSc, monocyte chemoattractant protein 1 expression by fibroblasts, 1382
Childhood Health Assessment Questionnaire, functional outcome scores in children with JRA, 1768
Children
AS, hormone levels and birth order, 1476
AS, risk of in first-born, 1964, 1965
congenital heart block, anti-Ro/SSA antibodies and, 1723, 1832
familial Mediterranean fever, musculoskeletal manifestations of in, 1416
heart rate-corrected QT interval in children of anti-Ro-positive mothers, 242, 243
juvenile arthritis, functional outcome scores in, 1768
juvenile DM, cholestasis in, 1139
Kawasaki disease, monocyte chemoattractant protein 1 polymorphism and serum levels in, 2211
uveitis, etanercept therapy in treatment-resistant disease, 1411
Chimeric molecules
Ad5.fib16 vectors for gene transfer to synovium, 570
anti-CD20 chimeric monoclonal antibody therapy for WG, 2836
serum sickness secondary to treatment with rituximab, 1717
Chinese population, knee OA in elderly, 2065
Chlamydia trachomatis
changes induced by in reactive arthritis, 2392
chlamydial DNA in synovial fluid of early undifferentiated oligoarthritis, 2679
synovial fluid-PCR detection of pathogens, 2463
Choctaw population, SSc, fibrillin 1 single-nucleotide polymorphism in, 893
Cholestasis, in juvenile DM, 1139
Chondrocytes
antiapoptotic effect of hyaluronan, 1800
antisense inhibition of CD44 exon 19, 2599
autologous chondrocyte implantation, cartilage repair and, 2586
CD95-induced apoptosis in, 1644
cyclic tensile strain inhibits TNFα-induced genes, 2311
glucosamine and IL-1β in rats, 351
mitochondrial respiration in articular chondrocytes, NO and, 96
MMP-1, synergistic induction by IL-1α and oncostatin M, 2296
molecular markers of stable chondrocytes, 1608
OA, C-C chemokines and receptors in, 1056
OA, cathepsin B in, 1819
OA, hepatocyte growth factor induction of collagenase 3 production in, 73
OA, MMP and proinflammatory cytokine production by chondrocytes in, 585
OA, selection of new therapeutic targets, 1239
peroxisome proliferator-activated receptor γ agonists inhibit activation of, 595
RA, Sox9 and type IIA procollagen in murine OA, 947
RANTES production and cartilage degradation, 1633
YKL-40 production by, regulation of, 826
Chondrogenesis, fibroblast-mediated delivery of growth factor complementary DNA in mouse joints, 1943
Chondrogenic potential, of periosteum-derived cells throughout expansion, 85
Chondroitin, renal toxicity, 2943
Chromosome 6p22-23, susceptibility locus for Behçet's disease, 2693
Chromosome 16p, susceptibility locus in familial hip OA, 2548

Chromosomes, linkage analysis of SLE-related traits, 2807
Churg-Strauss syndrome
classification criteria, differentiation from WG by artificial neural network, 1887
IL-4 and IL-13 production by T cell lines in, 469
long-term followup, 666
treatment of, 508
Cigarette smoking, disease outcome in early inflammatory polyarthritis and, 323
Circulating endothelial cells, in SLE, 1203
Citrullinated peptide
anti-citrulline-containing peptide antibody-producing B cells in RA synovial fluid, 41
in RA synovium, 2255
Clodronate
intraarticular liposomal, in antigen-induced arthritis, 1908
mechanism, in vivo, 2201
Clusterin, at surface of bovine articular cartilage, 1795
Cognitive function, in fibromyalgia, 2125
Colchicine, for Behçet's syndrome, 2686
Collagen
cartilage turnover and inflammation in RA joints, 2503
degradation of types IX and II, in experimental inflammatory arthritis, 120
FTIR spectral imaging of cartilage, 846
JRA, autoimmunity to type II and, 1775
procollagenase activation in cartilage breakdown, 2084
Sox9 and type IIA procollagen in murine OA, 947
synergistic effects of IL-6 and IL-1 on cartilage degradation, 1620
type II, oral tolerance for RA, 1993
Collagenase
1, suppression of, by ML-3000, dog model, 2320
3, hepatocyte growth factor in OA, 73
Collagen-induced arthritis
chronic homologous, for testing therapies, 1215
complement regulators and, 2425
estrogen receptor blockade exacerbation in mice, 2168
IFNγ and, in nonsusceptible mouse strain, 2413
intracellular IL-1 receptor antagonist type I in, 451
lymphocyte activation and differentiation in, 1438
oncostatin M inhibition, amelioration in murine models, 2697
resistance to in CD44-deficient DBA/1 mice, 2922
superoxide dismutase mimetic M40403 and, 2909
tissue inhibitor of MMP-1 gene transfer in, 1444
treatment by extracellular superoxide dismutase gene transfer, 2160
type II, nasal dosage in suppression of, 1917
Complement, C3 and C4 levels drop with renal and hematologic SLE, 2350
Complement activation, in RA, C-reactive protein and, 997
Complement regulators, collagen-induced arthritis and, 2425
Complementary DNA-array technology, OA, expression pattern analysis in cartilage using, 277
Congenital heart block
anti-Ro/SSA antibodies and, 1723, 1832
in Finnish population:, 487, 647
Connective tissue diseases, silicone breast implants and, 2477
Consensus peptides, anti-DNA-based peptide in murine lupus, 432
Corticosteroids, TNFα blockade and pulse corticosteroid effects on RA, 245
Corticotropin-releasing hormone
in arthritis, 782
signaling via R1α in joint inflammation, 1761
Coxsackie adenovirus receptor, Ad5.fib16 vectors for gene transfer to synovium, 570
C-reactive protein
complement activation mediated by, 997
inflammation and, 995
Criteria
ACR, RA improvement, 1052, 1719, 1720
AS, improvement criteria, 1728, 1876
juvenile arthritis, functional outcome scores in children, 1768
Sapporo, for APS, 1965
SSc, updating ACR preliminary classification, 735
Crry, collagen-induced arthritis and, in rat model, 2425
Cryoglobulinemia, hepatitis C virus-associated mixed cryoglobulinemia, risk of and HLA-DR phenotype, 2118
CXCL13 (B cell–attracting chemokine 1), in SS, 2633
Cyclic tensile strain, temporomandibular joint, cyclic tensile strain and effects of IL-1β in rabbits, 608
Cyclooxygenase (COX), ML-3000, in vivo dual inhibition of, and lipoxygenase in experimental OA, 2320
COX-2, migration inhibitory factor, activation of RA synoviocytes, 1273
COX-2 inhibitors
celecoxib for AS, 180
thrombosis and, 984, 1229, 1230
Cysteine protease, rat arthritis model, 703
Cytokines. *See also* Interferon and Interleukin
autoimmunity and RA, 2218
cartilage degradation, synergistic effects of IL-6 and IL-1 on, 1620
CDDO inhibits induction of MMP-1 and MMP-13, 1096
Churg-Strauss syndrome, IL-4 and IL-13 production by T cell lines in, 469
Ets-1 overexpression in RA synovial membrane, 266
IL-17 tunes expression of, 2176
IL-18 and NK cell death, 884
IL-18 for inflammatory rheumatic disease, 1481
JIA, gene polymorphisms and susceptibility to, 802
lymph draining from foot joints in RA and, 541
MMP and proinflammatory, production by chondrocytes in OA cartilage, 585
production of, by tenosynovium and tendon destruction in RA, 1754
proinflammatory, role in OA, 1237
TNFα blockade combined with IL-1 and IL-17 blockade,1293
TNFRII polymorphism and RA, in Caucasians, 61
type 1, secretion by C-II reactive T cells, 561

D

Decay-accelerating factor
collagen-induced arthritis and, in rat model, 2425
induction of by vascular endothelial growth factor, 138
Decker, John L., in memoriam, 1975
Demyelination, with TNFα antagonism, 197, 2862
Dendritic cells
alterations of, in SLE, 856
infiltration of autoimmune, and OA synovial tissue, 105
peripheral blood, alteration of in primary SS, 419
Depression, activity loss and onset of symptoms, 1194
Dermal fibroblasts. *See* Fibroblasts
Dermatomyositis (DM)
cholestasis in juvenile DM, 1139
PMS1 as myositis-specific autoantigen, 389
silicone breast implants and, 2477
Diacerein, in hip OA, ECHODIAH trial, 2539
Diclofenac, plus misoprostol, vs. acetaminophen for knee and hip OA, 1587
Diffuse proliferative lupus nephritis, Th1 immune response in, 2097
Diplopia, Brown's syndrome, 2460
Disability
inflammatory polyarthritis, early treatment with DMARDs to reduce, 1033
SSc, penicillamine trial using disability index as predictor of outcome, 653

Disease activity
RA, relationship between joint destruction, functional capacity and, 2009
RA, relationship between measures of outcome in, 2009
RA, strength training in early disease, 515
vasculitis, survival and, 2943
WG, Birmingham Vasculitis Activity Score for, 912
Disease flare
following GM-CSF treatment, in SLE, 2458, 2459
placebo effects in pain trials, 1599
Rheumatoid Arthritis Disease Activity Index, responsiveness to, 53
SLE, anti-dsDNA drops during, 2342
SLE, C3 and C4 levels drop with renal and hematologic SLE, 2350
Disease-modifying antirheumatic drugs (DMARDs). *See also names of individual drugs*
chronic homologous collagen-induced arthritis model used for testing of, 1215
inflammatory polyarthritis, early treatment with, 1033
minocycline and hydroxychloroquine, comparison of, 2235
Disease severity
AS, determinants of severity, 1396
Still's disease, IL-18 as indicator, 1716
Disintegrin metalloproteinase MDC15, expression of, in RA synovial tissue, 2046
Diterpenoid triepoxides, triptolide suppresses proMMP production, 2193
DNA
bacterial, in synovium of arthritis patients, 1689
Chlamydia and *Borrelia,* in synovial fluid of early undifferentiated oligoarthritis, 2679
chromosomal, from bacterial species in synovial tissue of arthritis patients, 1689
hypomethylation caused by decreased signaling, in SLE, 397
DNAase, in SLE, 2446
DNA mismatch repair enzymes, PMS1 is myositis-specific autoantigen, 389
Dog models, ML-3000, in vivo dual inhibition of cyclooxygenase and lipoxygenase by in experimental OA, 2320
Doxycycline, intravenous, in RA, 1043
DRB1 alleles
HLA-DRB1, and RA susceptibility, 535
RA-associated, overexpression of, 1281

E

E-selectin, adjuvant-induced arthritis in rats, 1428
ECHODIAH trial, diacerein for hip OA, 2539
Economics
musculoskeletal conditions, medical costs of, 1160
RA care, rheumatologists vs. generalists, 1504
RA, Markov model for morbidity, mortality, and cost of care for, 2746
RA, medical costs in early disease, 528
Elderly patients
age-related changes in knee joint cartilage morphology and deformation, 2556
arthritis and activity limitations in, 212
knee OA in Chinese population, 2065
Employees, rheumatology and health of workforce, 1971
Endothelial cells
B cell-attracting chemokine 1 (CXCL13) ectopic expression on, in SS, 2633
circulating activated endothelial cells in SLE, 1203
induction of decay-accelerating factor by vascular endothelial growth factor, 138
micro- and macrovascular AECA, 1484
statin inhibition of endothelial activation mediated by anti-β_2-glycoprotein I, 2870
Endothelium, ANCA promotes migration of neutrophils through, 2851
Enthesitis, resistant spondylarthropathy, etanercept for, 2122
Epidermal growth factor, 260
Epithelial neutrophil activating peptide 78, angiogenesis regulation in RA joint by, 31
Epstein-Barr virus (EBV), previous exposure and SLE, 1122
ErbB-2 protein, in rheumatoid synovial cell growth, 260
Erosion, time to first occurrence of in inflammatory polyarthritis, 1248
Estrogen
OA knee symptoms in postmenopausal women and, 811
Receptor blockade, exacerbation of collagen-induced arthritis in mice by, 2168
Etanercept
conventional treatment with, in WG, 1149
for entheseal pathology in resistant spondylarthropathy, 2112
for rheumatoid lymphedema, 240
for treatment-resistant uveitis in children, 1411
Ets-1, expression in RA synovial membrane, 266
Exercise, strength training in early RA, 515
Extracellular superoxide dismutase, treatment of murine collagen-induced arthritis with, 2160
Eyes
Brown's syndrome, diplopia in RA caused by, 2460
SLE, hydroxychloroquine macular toxicity during treatment, 1959
uveitis, etanercept therapy in children with treatment-resistant disease, 1411

F

F_2-isoprostanes as index of lipid peroxidation in Ssc, 1143
Familial Mediterranean fever
MICA modifier and, 163
musculoskeletal manifestations in children, 1416
Family studies
AS, hormone levels and birth order, 1476
AS, risk of in first-born children, 1964, 1965
OA, susceptibility locus on chromosome 16p in familial hip OA, 2548
RA, inheritance of, 2247
SSc, familial occurrence of, 1359
topoisomerase I-reactive T cells in SSc twins, 1654
widespread musculoskeletal pain, 481
Fas-mediated apoptosis
hyaluronan, antiapoptotic effect, 1800
predisposition to arthritis after *Mycoplasma pulmonis* infection, 2146
in RA synovial macrophages, 21
Fcγ receptors
for immunoglobulin G, 739
lupus nephritis, Fcγ receptor IIIA-158F allele as risk factor for, 618
SLE, low-binding alleles of types IIA and IIIA in, 361
Fcε receptors, SLE, FcεRIγ in, 1114
Ferritin, as predictor of iron deficiency in anemia of RA, 979
Fetal cell microchimerism
in SLE, 2107
in SSc, 1848
Fetal cell trafficking, and dermal fibrosis, 2944
Fibrillin 1
SSc, abnormalities in, 1855
SSc, single-nucleotide polymorphism in, 893
Fibroblast-like synoviocytes, Wnt-5A signaling in RA, 772
Fibroblasts
fibroblast-mediated delivery of growth factor complementary DNA in mouse joints, 1943
fibroblast-specific regulatory elements in murine *Col1a2,* 712
human parvovirus B19-induced synoviocyte invasiveness in, 1582
IL-17 synergizes with TNFα and fine-tunes IL-1, IL-6, and IL-8 in, 2176

Fibroblasts *(cont'd)*
RA, protein kinase Akt regulation of TNFα-mediated apoptosis of, 1555
RA, triptolide suppresses proMMP production in, 2193
RA, VEGF expression by fibroblast-leukocyte interaction, 2512
regulation of synovial fibroblast invasion by p53, 676
SSc, blockade of endogenous TGFβ in fibroblasts, 474
SSc, decreased apoptosis in, 1667
SSc, fibrillin 1 abnormalities in dermal cultures in, 1855
SSc, monocyte chemoattractant protein 1 expression by, 1382
SSc, oxidative stress in, 2653
SSc, protein kinase C and tenascin in lung fibroblasts, 1370
SSc, up-regulated expression of TGFβ receptors, 731
Fibrochondrocytes, temporomandubular joint, cyclic tensile strain and effects of IL-1β in rabbits, 608
Fibromyalgia
alpha sleep characteristics in, 222
cognitive function in, 2125
pain and somatization, 751
silicone breast implants and, 2477
somatization as predictor of onset of chronic widespread pain, 940
Fibronectin, alternatively spliced EIIIA segment, 2572
Finnish population
HLA haplotypes in RA patients, 315
IL-10 microsatellites and reactive arthritis, 1209, 2212
isolated congenital heart block in, 487, 647
widespread musculoskeletal pain among twin pairs, 481
Flare. *See* Disease flare
FLIP
in experimental arthritis, differential expression pattern from Bcl-2, 2899
in RA synovial macrophages, 21
Fluoroscopy, steroid instillation into OA hip and, 2449
Flurbiprofen nitroxybutylester, HCT1026 and bone resorption and bone loss, 2185
Folates, effect on MTX treatment of RA, 1515
Foot joints, lymph draining from, cytokine and chemokine production and transport, 541
Fourier transform infrared spectral imaging, of collagen and proteoglycan in cartilage sections, 846
Fractalkine, in RA and rat adjuvant-induced arthritis, 1568
Fracture
alendronate and, in patients receiving glucocorticoids, 202
vertebral, relationship of health-related quality of life to, 2611
French population
ACR 1987 RA criteria, 2485
polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome, long-term followup of, 666
Functional capacity
RA, relationship between disease activity, joint destruction and, 2009
RA, relationship between measures of outcome in, 2009
Reactive arthritis, Childhood HAQ functional outcome scores in children with, 1768

G

Gelatinase A/B, MMPs in Lyme arthritis, 1401
Gene therapy, IKKβ as regulator of inflammation, 1897
Gene transfer. *See also* Genetics; Mutations; Polymorphisms
Ad5.fib16 vectors for gene transfer to synovium, 570
collagen-induced arthritis, TIMP-1 gene transfer in, 1444
collagen-induced arthritis, treatment with extracellular superoxide dismutase gene transfer, 2160
fibroblast-mediated delivery of growth factor complementary DNA in mouse joints, 1943
IL-6 gene polymorphism and bone resorption, 196
RA, adenovirus-mediated gene transfer in synovial fluid, 48
Gene transfer. *See also* Genetics; Mutations; Polymorphisms *(cont'd)*
SS, chronic sialadenitis treatment by *fasL* gene transfer in mice, 964
Genetic ablation, IFNγ and in nonsusceptible mouse strain, 2413
Genetics. *See also* Gene transfer; Mutations; Polymorphisms
anti-DNA-based peptide in murine lupus, 432
antisense inhibition of CD44 exon 19, 2599
AS, determinants of severity, 1396
Behçet's disease, linkage of HLA-B locus in, 239
Behçet's disease, mapping novel locus to chromosome 6p22-23, 2693
collagen-induced arthritis, TIMP-1 gene transfer in, 1444
cyclic tensile strain inhibits TNFα-induced genes, 2311
erratum, Moos article (Nov. 2000), 1715
failure to verify H-*ras* mutations in arthritis synovium, 2705
familial Mediterranean fever, MICA modifier and, 163
familial Mediterranean fever, musculoskeletal manifestations of, 1416
fibroblast-specific regulatory elements in murine *Col1a2,* 712
hereditary angioedema, C1 inhibitor gene mutation and, 974
HLA-DQβ1 domain and anti-topoisomerase I autoantibody response, 491
HOXD9 and synoviocyte proliferation, 1013
hypoxia-inducible factor 1α expression by macrophages in RA synovium, 1540
IL-6 gene, polymorphism and bone resorption, 196
IL-6 gene, single-base substitution by real-time PCR, 2213
immunoglobulin variable-region gene usage in systemic autoimmune diseases, 2715
JIA, cytokine gene polymorphisms and susceptibility to, 802
JIA, IL-1Ra gene polymorphism in, 2387
JIA, migration inhibitory factor polymorphism and systemic-onset JIA, 1782
lupus nephritis, Fcγ receptor IIIA-158F allele as risk factor for, 618
methylene tetrahydrofolate reductase (MTHFR) gene, C677T mutation in, 2525
musculoskeletal pain in twin pairs, 481
OA, expression pattern analysis in cartilage using complementary DNA-array technology, 277
OA, susceptibility locus on chromosome 16p in familial hip OA, 2548
OA, $VEGF_{121}$ and $VEGF_{189}$ expression in OA cartilage, 1082
RA, HLA haplotypes in, 315
RA, independent association of RF and HLA-DRB1 shared epitope with radiographic outcome, 1529
RA, inheritance of, 2247
RA, MICA polymorphisms in, 1261
RA, overexpression of RA-associated DRB1 molecules, 1281
RA, protease genes and erosion in early disease, 1744
RA, shared epitope-negative HLA-DRB1 alleles and genetic susceptibility to, 535
RA, single-nucleotide ppolymorphism in *SAA1* gene and risk of AA amyloidosis in, 1266
RA, in southern Spain, 307
RA, TNF and sex influences on HLA-associated RA risk, 286
RA, TNFRII polymorphism in Caucasians, 61
RA, Wnt-5A signaling in, 772
SLE, DNA hypomethylation by decreased signaling in, 397
SLE, glutathione S-transferase null alleles and, 981
SLE, linkage analysis of SLE-related traits, 2807
SLE, low-binding Fcγ alleles, 361
SLE, prolactin gene polymorphism and, 2358
SLE, T cell receptor gene mutations/polymorphisms and splice variations, 1336
SLE, TNFRII polymorphism 196R association with, 2819
SS, IL-10 haplotypes in, 176
SS, immunoglobulin V_δ light chain gene usage in, 2620
SS, immunoglobulin V_κ light chain gene analysis in, 626

Genetics. *See also* Gene transfer; Mutations; Polymorphisms *(cont'd)*
SS, *Ro52* polymorphisms in, 638
SSc, cytochrome P2 polymorphisms and susceptibility to, 662, 2705, 2706
SSc, fibrillin 1 single-nucleotide polymorphism, 893
tight-skin phenotype in immune-deficient mice, 723
Germinal center reaction, in murine collagen-induced arthritis, 1438
Germinal center-like structures, BCA-1 (CXCL13) expression and in SS, 2633
Giant cell arteritis (GCA), infliximab for, 2933
Ginger, OA treatment with, 2461, 2531
Glucocorticoid-induced osteoporosis, prevention and treatment of, 1496
Glucocorticoids
alendronate in patients receiving, effect on BMD and vertebral fracture, 202
fluoroscopically directed steroid instillation in hip arthritis, 2449
intraarticular, joint damage mediators in OA synovium and, 343
Glucosamine
IL-1β and, in rat chondrocytes, 351
renal toxicity and, 2943
uptake of, in articular cartilage explants, 1089
Glucuronosyltransferase I, glucosamine and IL-1β in rat chondrocytes, 351
Glutathione S-transferase, SLE and, 981
Gluteus medius pathology, in greater trochanteric pain syndrome, 2138
Glycation, age-related decrease in susceptibility of cartilage to MMP-mediated degradation, 2562
Glycoprotein 130 binding cytokines
Chlamydia trachomatis -induced up-regulation in reactive arthritis, 2392
synergistic effects of IL-6 and IL-1 on cartilage degradation, 1620
Gout
densensitization to allopurinol following cutaneous reactions, 231
differentiated dendritic cell infiltration of synovial tissue, 105
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
IL-1-induced arthritis and, 111
SLE flare resulting from treatment, 2458, 2459
Granzyme, SS autoantigen α-fodrin and type 3 muscarinic acetylcholine receptor cleavage by, 2376
Greater trochanteric pain syndrome, MRI and physical examination findings, 2138

H

H-*ras* mutations, failure to verify in arthritis synovium, 2705
Hands, hereditary angioedema, C1 inhibitor gene mutation and, 974
HCT1026, as inhibitor of bone resorption and bone loss, 2185
Health Assessment Questionnaire (HAQ), high-dose vs. low-dose penicillamine SSc trial, disability index as predictor of outcome, 653
Health-related quality of life, of prevalent and incident vertebral fractures and, 2611
Health care costs. *See* Economics
Heart. *See also* Cardiovascular disease
arthritis as predictor of cardiovascular disease-related death, 1170
cardiovascular mortality of RA, role of rheumatic disease in, 2707
heart rate-corrected QT interval in children of anti-Ro-positive mothers, 242, 243
Libman-Sacks endocarditis, 2111
RA, cardiovascular events in not explained by traditional cardiac risk factors, 2737
Heart block
anti-Ro/SSA antibodies, congenital heart block and, 1723, 1832
isolated congenital heart block in, 487, 647
Hemarthrosis, in type 1 neurofibromatosis, 2134
Hematopoietic stem cell transplantation, in RA, 754
Hepatitis, with interface inflammation and anti-double-stranded DNA antibodies following infliximab therapy for RA, 1966, 1968
Hepatitis B infection
with MTX therapy in RA, 339
synovial stimulatory protein fragments copurify with woodchuck hepatitis virus, 486
Hepatitis C virus-associated mixed cryoglobulinemia, risk of and HLA-DR phenotype, 2118
Hepatocyte growth factor, and induction of collagenase 3 production in OA cartilage, 73
Hepatotoxicity
acetaminophen for OA patients with liver disease, 2448
RA, methylene tetrahydrofolate reductase gene mutation and risk of MTX liver damage, 2525
Hereditary angioedema, C1 inhibitor gene mutation and, 974
Hip
OA, acetaminophen for alcoholic patients, 2449
OA, acetaminophen for patients with liver disease, 2448
OA, ACR recommendations for management, comments on, 2448, 2449, 2450, 2451, 2455
OA, diacerein for, ECHODIAH trial, 2539
OA, diclofenac plus misoprostol vs. acetaminophen, 1587
OA, fluoroscopically directed steroid instillation in, 2449
OA, susceptibility locus on chromosome 16p in familial OA, 2548
Hispanic population
arthritis prevalence and activity limitations in older adults, 212
low-binding Fcγ alleles in SLE, 361
SLE, glutathione S-transferase null alleles and, 981
SLE, predictors of damage in LUMINA cohort, 2797
HLA haplotypes, in RA, 315
HLA-B27 bound peptide, alterations induced by *Salmonella typhimurium*, 1677
HLA-DQβ1 domain, anti-topoisomerase I antibodies and, 491
HLA-DR phenotype, risk of hepatitis C virus-associated mixed cryoglobulinemia and, 2118
HLA-DRB1 alleles
RA, independent association of RF and HLA-DRB1 shared epitope with radiographic outcome, 1529
RA, overexpression of RA-associated DRB1 molecules, 1281
RA, susceptibility and, 535
RA, TNF and sex influences on HLA-associated risk, 286
Homeobox (*HOX*) genes, *HOXD9* and synoviocyte proliferation, 1013
Host defense scavenger receptors, in spondylarthropathy, 931
HOXD9, in synoviocyte proliferation, 1013
Human cartilage glycoprotein (YKL-40), regulation of production by chondrocytes, 826
Human parvovirus B19, B19-induced synoviocyte invasiveness in fibroblasts, 1582
Hyaluronan, antiapoptotic effect of, 1800
Hydroxychloroquine
macular toxicity during SLE treatment, 1959
minocycline and hydroxychloroquine, comparison for early seropositive RA, 2235
Hylan G-F 20
injected, bilateral symmetric inflammatory reaction to, 978
for intraarticular OA of the knee, 1470, 1471, 1473
Hyperprolactinemia, prolactin-IgG complex in SLE, 866
Hyperuricemia, densensitization to allopurinol following cutaneous reactions, 231
Hypothalamic-pituitary-adrenal/gonadal axis, in RA, 493
Hypoxia-inducible factor 1α, expression by macrophages in RA, 1540

I

Icelandic population
OA, susceptibility locus on chromosome 16p in familial hip OA, 2548
RA, inheritance of, 2247

IDEC-C2B8 (rituximab) treatment, serum sickness with, 1717
Imaging
2000 Slide Competition winners, 513
adjuvant-induced arthritis, cysteine protease activity up-regulation in ankle joints, 703
adjuvant-induced arthritis , SB 273005 in rat model, 128
adjuvant-induced arthritis , selectins and, 1428
alterations in HLA-B27-bound peptide repertoire induced by *Salmonella typhimurium*, 1677
amyloid myopathy case study, 1954
antigen-induced arthritis, intraarticular liposomal clodronate in, 1908
arthritis in mycoplasma-infected mice, defective Fas ligand-mediated apoptosis and, 2148
arthritis susceptibility and resistance in C3H mice, 682
aseptic prosthesis loosening, 956
autoantigen proteolysis in secondary necrosis, 2642
autologous chondrocyte implantation, cartilage repair and, 2586
blastomycosis-induced arthritis, 492
Borrelia burgdorferi in Lyme arthritis, 151
Brown's syndrome, diplopia in RA, 2460
cartilage intermediate-layer protein, role in arthropathy in OA and RA, 838
CD44 exon 19, antisense inhibition of, 2599
cervical spinal cord compression, 241
chondrocyte activation, peroxisome proliferator-activated receptor γ agonists inhibit, 595
citrullinated proteins, in RA synovium, 2255
collagen-induced arthritis, chronic homologous, for testing therapies, 1215
collagen-induced arthritis, germinal center reaction in mouse joints, 1438
collagen-induced arthritis, intracellular IL-1Ra type I in, 451
collagen-induced arthritis, membrane complement regulators and, 2425
collagen-induced arthritis, TIMP gene transfer in, 1444
collagen-induced arthritis, treatment with extracellular superoxide dismutase gene transfer in mice, 2160
corticotropin-releasing hormone R1β, signalingin joint inflammation, 1761
diffuse proliferative lupus nephritis, Th1 immune response in, 2097
DM, cholestasis in juvenile form, 1135
fibroblast-mediated delivery of growth factor complementary DNA in mouse joints, 1943
fibroblast-specific regulatory elements in murine *Col1a2*, 712
Fourier transform infrared spectral imaging of cartilage, 846
fractalkine in RA and rat adjuvant-induced arthritis, 1568
greater trochanteric pain syndrome, MRI and physical examination in, 2138
IFNγ and in nonsusceptible mouse strain, 2413
IKKβ as regulator of synovial inflammation, 1897
IL-1 arthritis, dependence on GM-CSF, 111
IL-1-dependent acute arthritis, 442
inflammatory polyarthritis, time to first occurrence of erosions in, 1248
Libman-Sacks endocarditis, 2111
mesenchymal stem cells from human synovium, 1928
ML-3000, dual inhibition of cyclooxygenase and lipoxygenase in experimental OA, 2320
molecular markers of stable chondrocytes, 1608
MRI, age-related structural modifications of bovine articular cartilage, 2285
MRI, of metacarpophalangeal joints, 2492
NURR1 and corticotropin-releasing hormone in arthritis, 782
OA, antiapoptotic effect of hyaluronan, 1800
OA, apoptosis in normal and OA cartilage, 1304
OA, C-C chemokines and receptors in, 1056
Imaging *(cont'd)*
OA, cathepsin B in OA cartilage and cultured chondrocytes, 1819
OA, cell clusters in rabbit meniscus, 1808
OA, differentiated dendritic cell infiltration of synovial tissue, 105
OA, intraarticular glucocorticoids and joint damage mediators in synovium, 343
OA, MMP and proinflammatory cytokine production by chondrocytes in, 585
OA, MMPs and aggrecanase in OA lesions, 1455
OA, MRI assessment of cartilage loss in severe disease, 2072
OA, plasma cell membrane glycoprotein 1 in knee meniscal cartilage matrix calcification, 1071
OA, radioanatomic alignment and progression of knee, 1786
OA, Sox9 and type IIA procollagen in mouse models, 947
OA, susceptibility locus on chromosome 16p in familial hip OA, 2548
OA, $VEGF_{121}$ and $VEGF_{189}$ expression in cartilage, 1082
OA and RA, *HOXD9* and synoviocyte proliferation, 1013
OA and RA, power Doppler sonography and vascularity of synovial tissue in knee joint, 331
periosteal cells, 85
polymyalgia rheumatica, inflamed shoulder structures in, with normal ESR, 1155
powerDopplersonographyinassessmentofsynovitisinmetacarpophalangeal joints in RA, 2018
RA, Akt to regulate TNFα-mediated apoptosis of synovial fibroblasts, 1555
RA, amyloid fat deposits in, 66
RA, Brown's syndrome in, 2460
RA, chemokine receptor expression on monocytes, 1022
RA, disintegrin metalloproteinase MDC15 (metargidin) expression in synovial tissue, 2046
RA, ErbB-2 protein in synovial cell growth, 260
RA, Ets-1 expression in synovial membrane, 266
RA, FLIP expression in synovial macrophages, 21
RA, hypoxia-inducible factor 1α expression in, 1540
RA, immunostaining of synovial tissue with antichemokine antibodies, 31
RA, infliximab therapy, hepatitis with interface inflammation and anti-double-stranded DNA antibodies, 1966
RA, MMP-9, apoptosis, and vascular morphology in early arthritis, 2024
RA, 3-nitrotyrosine distribution in synovium, 1534
RA, NK cell receptor-bearing T cells in, 13
RA, notch-1 protein and activation of RA synoviocytes, 1545
RA, osteoclastogenesis by activated T cells in, 1003
RA, overexpression of BiP in, 761
RA, prognostic factors for radiographic damage in early disease, 1736
RA, radiographic joint damage, 1231
RA, recombination-activating proteins in synovial tissue, 2275
RANTES production and role in cartilage degradation, 1633
regulation of synovial fibroblast invasion by p53, 676
relapsing polychondritis, matrilin 1 antibodies in, 2402
relapsing polychondritis, orbital mucosa-associated lymphoid tissue-type lymphoma associated with, 1713
resistant spondylarthropathy, etanercept for entheseal pathology, 2112
SLE cells in kidney and synovial fluid, 169
SLE, circulating activated endothelial cells in, 1203
SLE, microchimerism in, 2107
SLE, murine lupus and $SmD1^{83-119}$ peptide, 2435
small-vessel vasculitis surrounding spared temporal artery, 1387
spondylarthropathy, effects of anti-TNFα on synovium in, 186
SS, B cell-attracting chemokine 1 (CXCL13), 2633
SS, caspase 3 and Bax expression in, 693
SS, chronic sialadenitis treatment by *fasL* gene transfer in mice, 964

Imaging *(cont'd)*
SS, "lymphoid" chemokine mRNA expression in salivary glands, 408
SS, peripheral blood dendritic cells altered in, 419
SSc, decreased apoptosis in SSc fibroblasts, 1665
SSc, fetal cell microchimerism in, 1848
SSc, 5-lipoxygenase in SSc skin, 1865
SSc, monocyte chemoattractant protein 1 overexpressed in, 2665
SSc, oxidative stress in, 2653
type 1 neurofibromatosis, hemarthrosis in, 2134
ultrasonography for diagnosis and management of musculoskeletal conditions, 2932
YLK40, regulation of production by articular chondrocytes, 826
Immune system, innate immune system in RA, 2224
Immune Tolerance Network, 1730
Immunoadsorption, SLE treatment with C1q column, 1962
Immunoglobulin, κ light chains, secondary rearrangement of in RA synovial tissue, 2275
Immunoglobulin G
human receptors for, 739
prolactin-IgG complex in SLE, 866
Immunoglobulin variable-region gene usage, in systemic autoimmune diseases, 2715
Immunoglobulins
immunoglobulin V_δ light chain gene usage in SS, 2620
immunoglobulin V_κ gene rearrangements in SS, 626
Immunologic laboratory tests, in SLE, 2221
Immunomodulatory drugs, leflunomide, weight loss associated with, 1048
Immunosuppressant therapy
and autologous stem cell transplantation in RA, 754
hepatitis B after MTX discontinuation, 339
In memoriam
Decker, John L., 1975
Polley, Howard F., 1495
September 11th terrorist victims, 2447
Inducible NOS
deficiency of in antigen-induced arthritis, 1420
inflammation-induced osteoporosis, 2790
Inflammation
arthritis as predictor of cardiovascular disease-related death, 1170
C-reactive protein and, 995
damage and inflammation in individual joints in early RA, 2243
IKKβ as regulator of, 1897
IL-10 and IL-4 synergism in suppression of inflammation and joint destruction in RA, 3
IL-17 synergizes with TNFα and fine-tunes IL-1, IL-6, and IL-8, 2176
VCAM-1 and, 985
Inflammatory bowel disease, spondylarthropathy and, 2728
Inflammatory polyarthritis
cigarette smoking and disease outcome in early disease, 323
early treatment with DMARDs reduces disability, 1033
time to first occurrence of erosions in, 1248
Infliximab
For GCA, 2933
for RA, hepatitis with interface inflammation and anti-double-stranded DNA antibodies following, 1966, 1968
for severe AS, 2936
for spondylarthropathy, effects on synovium, 186
for SS, 2371
Inhibitor of NF-κB kinase β (IKKβ), 1897
Innate immune system, in RA, 2224
Interferon-γ (IFNγ)
and collagen-induced arthritis in nonsusceptible mouse strain, 2413
IFNγ-inducing activity of IL-18 in RA joint, 275
Interleukin-1 (IL-1)
cartilage degradation, synergistic effects of IL-6 and IL-1 on, 1620
Interleukin-1 (IL-1) *(cont'd)*
IL-1-induced arthritis and GM-CSF, 111
IL-17 synergizes with TNFα and fine-tunes IL-1, IL-6, and IL-8, 2176
mediators of IL-1-dependent acute arthritis, 442
RA, combination of TNFα blockade with IL-1 and IL-17 blockade for, 1293
synergistic induction of MMP-1 by IL-1α and oncostatin M in chondrocytes, 2296
Interleukin-1 receptor antagonist (IL-1Ra)
gene polymorphism in JIA, 2387
type I, in collagen-induced arthritis, 451
Interleukin-1β (IL-1β)
chondrocyte activation, peroxisome proliferator-activated receptor γ agonists inhibit, 595
chondrocytes, glucosamine and in rat models, 351
IFNγ and, in nonsusceptible mouse strain, 2413
suppression by ML-3000, dog model, 2320
temporomandubular joint, cyclic tensile strain and effects of IL-1β in rabbits, 608
Interleukin-4 (IL-4)
production by T cell lines in Churg-Strauss syndrome, 469
suppression of inflammation and joint destruction in RA, synergism with IL-10, 3
Interleukin-6 (IL-6)
IL-6 gene polymorphism and bone resorption, 196
IL-6 gene, single-base substitution by real-time PCR, 2213
IL-17 synergizes with TNFα and fine-tunes IL-1, IL-6, and IL-8, 2176
synergistic effects of IL-6 and IL-1 on cartilage degradation, 1620
Interleukin-8 (IL-8)
angiogenesis regulation in RA joint by, 31
IL-17 synergizes with TNFα and fine-tunes IL-1, IL-6, and IL-8, 2176
Interleukin-10 (IL-10)
RA, suppression of inflammation and joint destruction, synergism with IL-4, 3
Reactive arthritis, IL-10 microsatellites and, 1209, 2212
SS, promoter region polymorphisms and, 176
Interleukin-11 (IL-11), for lupus-induced thrombocytopenia, 170
Interleukin-13 (IL-13), production by T cell lines in Churg-Strauss syndrome, 469
Interleukin-17 (IL-17)
RA, combination of TNFα blockade with IL-1 and IL-17 blockade for, 1293
synergizes with TNFα and fine-tunes IL-1, IL-6, and IL-8, 2176
Interleukin-18 (IL-18)
adult-onset Still's disease and, 550, 1716
for inflammatory rheumatic disease, 1481
NK cell death and, 884
RA joint and, 275
Intracellular adhesion molecule 1 (ICAM-1), APS-induced pregnancy loss and, 1225
Intravenous immunoglobulin, for APS, amelioration mechanism, 876
Iron deficiency, ferritin and serum transferrin receptor as predictors of, in RA, 979
Isoxazole drugs, leflunomide, weight loss associated with, 1048

J

Japanese population
HLA-DQβ1 domain and anti-topoisomerase I autoantibody response, 491
Kawasaki disease, monocyte chemoattractant protein 1 polymorphism and serum levels, 2211
SLE, association of TNFRII polymorphism 196R in, 2819
SSc, fibrillin 1 single-nucleotide polymorphism in, 893
SSc, microchimerism with, 1226

Joint damage
adjuvant-induced arthritis, cysteine protease activity up-regulation in, 703
cartilage degradation, synergistic effects of IL-6 and IL-1, 1620
cartilage intermediate-layer protein role in, 838
cyclic tensile strain inhibits TNFα-induced genes in chondrocytes, 2311
MMP-1, synergistic induction of by IL-1α and oncostatin M in chondrocytes, 2296
MRI, of metacarpophalangeal joints, 2492
OA, C-C chemokines and receptors and, 1056
OA, cell clusters in rabbit meniscus, 1808
OA, intraarticular glucocorticoids and joint damage mediators in synovium, 343
OA, MRI assessment of cartilage loss in severe disease, 2072
OA, plasma cell membrane glycoprotein 1 in knee meniscal cartilage matrix calcification, 1071
OA, Sox9 and type IIA procollagen in mouse model, 947
procollagenase activation in cartilage breakdown, 2084
RA, damage and inflammation in individual joints in early disease, 2243
RA, IL-10 and IL-4 synergism in suppression of inflammation and joint destruction in, 3
RA, MMP-1, MMP-3, and TIMP-1 serum levels and, 2263
RA, protease genes and erosion in early disease, 1744
RA, radiographic joint damage in, 1231
RA, relationship between disease activity, functional capacity and, 2009
RA, relationship between measures of outcome in, 2009
RA, strength training in early disease, 515
RANTES, role in, 1633
VEGF serum level and destructive changes in inflammatory arthritis, 2055
Juvenile DM, cholestasis in, 1139
Juvenile idiopathic arthritis (JIA)
cytokine gene polymorphisms and susceptibility to, 802
IL-1Ra polymorphism in, 2387
migration inhibitory factor polymorphism and systemic-onset JIA, 1782
Juvenile rheumatoid arthritis (JRA)
angiogenic factors in, 794
autoimmunity to type II collagen and, 1775
cervical spinal cord compression in, 241
childhood HAQ functional outcome scores in children with, 1768
increased mortality in adults, 523
treatment-resistant uveitis, etanercept therapy for, 1411

K

Kawasaki disease, monocyte chemoattractant protein 1 polymorphism and serum levels in, 2211
Kidneys
glucosamine and renal toxicity, 2943
lupus nephritis, Fcγ receptor IIIA-158F allele as risk factor for, 618
SLE cells in, 169
SSc, renal crisis and pulmonary hypertension without interstitial lung disease, 1663
Th1 immune response in diffuse proliferative lupus nephritis, 2097
Killer immunoglobulin-like receptor (KIR) autoantibodies, in systemic autoimmune diseases, 384
Knee
acupuncture for OA, 819
age-related changes in cartilage morphology and deformation, 2556
collagen-induced arthritis, membrane complement regulators and, 2425
meniscal cartilage matrix calcification, plasma cell membrane glycoprotein 1 in, 1071
OA, acetaminophen for alcoholic patients, 2449
Knee *(cont'd)*
OA, acetaminophen for patients with liver disease, 2448
OA, ACR recommendations for management, critiques, 2448, 2455
OA, apoptosis in cartilage, 1304
OA, diclofenac plus misoprostol vs. acetaminophen, crossover clinical trial, 1587
OA, estrogen plus progestin in postmenopausal women, 811
OA, ginger extract for pain, 2531
OA, hylan G-F 20 injection, bilateral symmetric inflammatory reaction to, 978
OA, hylan G-F 20 treatment for, 1470, 1471, 1473
OA, in elderly Chinese population, 2065
OA, intraarticular glucocorticoids and joint damage mediators in, 343
OA, MRI assessment of cartilage loss in severe disease, 2072
OA, questionnaire screening for, 1105
OA, radioanatomic alignment and progression of, 1786
OA, Sox9 and type IIA procollagen in mouse model, 947
OA, up-regulation of NO and prostaglandin E_2 in meniscus, 2078
OA and RA, power Doppler sonography and vascularity of synovial tissue in, 331
Ku antigen, autoantibodies in SLE, 2367

L

Leflunomide
treatment in RA, 1985
weight loss associated with treatment in RA, 1048
Leukocytes, RA, VEGF expression by fibroblast-leukocyte interaction, 2512
Leukotrienes, 5-lipoxygenase overexpression in SSc skin, 1865
Lipid peroxidation, in SSc, 1143
Lipoprotein markers, in RA, 2761
Liposomal clodronate
intraarticular, in antigen-induced arthritis in rabbits, 1908
mechanism of action in vivo, 2201
Lipoxygenase, ML-3000, in vivo dual inhibition of COX and, in experimental OA, 2320
5-lipoxygenase, overexpression in SSc skin, 1865
Low-affinity peptides, overexpression of RA-associated HLA-DR alleles and, 1281
Lungs. *See* Pulmonary disease
Lupus nephritis
Fcγ receptor IIIA-158F allele as risk factor for, 618
Th1 immune response in diffuse proliferative lupus nephritis, 2097
Lyme arthritis
3-dimensional in vitro model, 151
host MMPs in, 1401
Lymph, from RA foot joints, cytokine and chemokine production and transport, 541
Lymphocytes
collagen-induced arthritis, activation and differentiation of, in, 1438
RA, CD20+,CD38- B lymphocyte response in synovium, 2029
RA, chemokine receptor expression in, 2750
Lymphoid cells, alterations in HLA-B27-bound peptide alterations induced by *Salmonella typhimurium*, 1677
"Lymphoid" chemokines, mRNA expression of in salivary glands of SS, 408
Lymphoma, relapsing polychondritis, orbital mucosa-associated lymphoid tissue-type, associated with, 1713
Lymphopenia, therapy-induced, in RA, morbidity and mortality and, 1998

M

Macrophage inflammatory protein 1α, and MMP-8, systemic inflammation in RA, 2940

Macrophages
OA, intraarticular glucocorticoids and macrophage infiltration in synovium, 343
RA, activation of synoviocyte phospholipase A_2 and COX 2 by migration inhibitory factor, 1273
RA, FLIP expression and Fas-mediated apoptosis in synovial macrophages, 21
RA, hypoxia-inducible factor 1α, expression by, in synovium, 1540
TIA-1 to regulate TNFα production in, 2879
Magnetic resonance imaging (MRI)
articular cartilage, structural evaluation of, 2285
cartilage loss in severe OA, 2072
etanercept for entheseal pathology in resistant spondylarthropathy, 2112
in greater trochanteric pain syndrome, 2138
of MCP joints, 2018, 2492
synovitis in RA MCP joints, compared with power Doppler sonography, 2018
Major histocompatibility complex (MHC) class I chain-related gene A (MICA)
modifier of, in familial Mediterranean fever, 163
polymorphisms of, in RA, 1261
Malignancy, relapsing polychondritis, orbital mucosa-associated lymphoid tissue-type lymphoma associated with, 1713
Markers
molecular, of stable chondrocytes, 1608
Still's disease, IL-18 as diagnostic, 1716
TNF, sex-influenced association with RA, 286
Markov model, morbidity, mortality, and cost of care for RA, 2746
Matrilin 1 antibodies, in relapsing polychondritis, 2402
Matrix metalloproteinase (MMP)
collagen-induced arthritis, TIMP gene transfer in, 1444
Lyme arthritis, 1401
mediated degradation, age-related decrease in susceptibility of cartilage to, 2562
in OA lesions, 1455
production of, by chondrocytes in OA, 58
RA, cartilage turnover and inflammation in joints, 2503
RA, production of, by tenosynovium and tendon destruction, 1754
RA, triptolide suppresses proMMP production, 2193
Matrix metalloproteinase 1 (MMP-1)
CDDO inhibits induction of, 1096
RA, protease gene expression and joint erosion in early disease, 1744
RA, serum levels in, 2263
synergistic induction of, by IL-1α and oncostatin M in chondrocytes, 2296
Matrix metalloproteinase 3 (MMP-3)
cartilage turnover and inflammation in RA joints, 2503
RA, serum levels in, 2263
RA, triptolide suppresses proMMP-1 production in, 2193
Matrix metalloproteinase 8 (MMP-8), and macrophage inflammatory protein 1α, and systemic inflammation in RA, 2940
Matrix metalloproteinase 9 (MMP-9), apoptosis and vascular morphology in early arthritis and, 2024
Matrix metalloproteinase 13 (MMP-13)
CDDO inhibits induction of, 1096
peroxisome proliferator-activated receptor γ agonists inhibit chondrocyte activation, 595
MDC15. *See* Metargidin
Medical costs
expenditures for musculoskeletal conditions, 1160
in early RA, 528
RA care, rheumatologists vs. generalists, 1504
Membrane complement regulators, collagen-induced arthritis and, 2425
Meniscus
cell clusters in OA rabbit meniscus, 1808
up-regulation of NO and prostaglandin E_2 in OA knee, 2078
Mesenchymal stem cells, from human synovium, 1928
Metacarpophalangeal (MCP) joints
MRI of, 2492
power Doppler sonography in assessment of synovitis in RA, 2018
Metargidin, expression in RA synovial tissue, 2046
Methotrexate (MTX)
folate supplementation with, 1515
for RA, hepatitis B after discontinuation of, 339
for RA, leflunomide compared with, 1984
for RA, methylene tetrahydrofolate reductase gene mutation and risk of liver damage, 2525
for SSc, early diffuse disease, 1351
Methylene tetrahydrofolate reductase gene, C677T mutation in, 2525
Microchimerism
dermal fibrosis, fetal cell trafficking and, 2944
fetal cell, in SSc, 1848
in SLE, case study, 2107
in SSc, 1226
Microfibrils, fibrillin 1 containing, in SSc dermal fibroblast cultures, 1855
Microsatellites, IL-10, and reactive arthritis, 1209, 2212
Microscopic polyangiitis
long-term followup, 666
myeloperoxidase-ANCA and proteinase 3-ANCA to activate PMN cells in, 921
pro-proteinase 3-reactive ANCA and disease activity in, 463
treatment of, 508
Migration inhibitory factor
polymorphism and systemic-onset disease in JIA, 1782
RA, regulation of synoviocyte phospholipase A_2 and COX 2 by, 1273
Miniarthroscopy, of MCP joints, 2492
Minocycline, and hydroxychloroquine, comparison for early seropositive RA, 2235
Misoprostol, plus diclofenac, vs. acetaminophen for knee and hip OA, 1587
Mixed connective tissue disease, silicone breast implants and, 2477
Mixed cryoglobulinemia, hepatitis C virus-associated, risk of and HLA-DR phenotype, 2118
ML-3000, in vivo dual inhibition of COX and lipoxygenase by, in experimental OA, 2320
Monarticular arthritis
familial Mediterranean fever, musculoskeletal manifestations of, in, 1416
mediators of IL-1-dependent acute arthritis, 442
Monoclonal antibodies
anti-CD20 chimeric, therapy for WG, 2836
RA, 6C2/GD3+ T cells in, 296
RA, therapy-induced lymphopenia and morbidity and mortality, 1998
SS, monoclonal expansion of B cells in, 490
Monocyte chemoattractant protein 1
polymorphism and serum levels in Kawasaki disease, 2211
in SSc, 1382, 2665
Monocytes
oxygen radical release induced by ANCA in vitro in small-vessel vasculitis, 1698
RA, chemokine receptor expression on, 1022
RA, osteoclastogenesis by activated T cells in, 1003
small-vessel vasculitis, monocytic oxygen radical release induced by ANCA in vitro, 1698
Morbidity, RA, Markov model for, 2746
Mortality
cardiovascular, in rheumatic disease, 2707
cardiovascular disease-related, arthritis as predictor of, 1170

Mortality *(cont'd)*
increased in adults with JRA, 523
mothers of children with isolated heart block, 647
oligoarthritis, predictors of outcome, 1177
polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome, long-term followup of, 666
premature, in RA, 1234
RA, cardiovascular events not explained by traditional cardiac risk factors, 2737
RA, improvements in survival in, 1467
RA, Markov model for, 2746
RA, rheumatic disease in cardiovascular mortality of, 2707
RA, therapy-induced lymphopenia and, 1998
RA, total lymphoid irradiation for, 1525
SLE, autologous stem cell transplantation for refractory childhood, 728
SSc, improvement in skin thickening and improved survival, 2828
vasculitis, disease activity and survival, 2943
Mothers
of children with isolated heart block, 647
fetal cell microchimerism in SSc, 1848
heart rate-corrected QT interval in children of anti-Ro-positive mothers, 242, 243
Mouse models
adenoviral-based overexpression of TIMP-1 to reduce tissue damage, 2888
anti-DNA-based peptide in lupus, 432
antigen-induced arthritis, inducible NOS deficiency in, 1420
arthritis after *Mycoplasma pulmonis* infection in Fas/FasL mutants, 2146
arthritis susceptibility and resistance in C3H mice, 682
chronic homologous collagen-induced arthritis for testing therapies, 1215
collagen-induced arthritis, estrogen receptor blockade exacerbation in, 2168
collagen-induced arthritis, IFNγ and, in nonsusceptible strain, 2413
collagen-induced arthritis, intracellular IL-1 receptor antagonist type I in, 451
collagen-induced arthritis, lymphocyte activation and differentiation in, 1438
collagen-induced arthritis, resistance to, in CD44-deficient DBA/1 mice, 2922
collagen-induced arthritis, TIMP-1 gene transfer in, 1444
collagen-induced arthritis, treatment by extracellular superoxide dismutase gene transfer, 2160
collagen-induced arthritis, type II collagen nasal dosage in, 1917
fetal cell trafficking and dermal fibrosis, 2944
fibroblast-mediated delivery of growth factor complementary DNA in joints, 1943
fibroblast-specific regulatory elements in *Col1a2,* 712
IL-1-dependent acute arthritis, mediators of, 442
IL-1-induced arthritis and GM-CSF, 111
inducible NOS pathway and inflammation-induced osteoporosis, 2790
JRA, angiogenic factors in, 794
OA, MMPs and aggrecanase in lesions, 1455
OA, Sox9 and type IIA procollagen, 947
oncostatin M inhibition ameliorates arthritis in, 2697
regulation of synovial fibroblast invasion by p53, 676
SLE, nucleosome kinetics in, 1320
SLE, $SmD1^{83-119}$ peptide, strong acceleration of murine lupus by injection of, 2435
SS, caspase 3 and Bax expression in, 693
SS, chronic sialadenitis treatment by *fasL* gene transfer, 964
tight-skin phenotype in immune-deficient strains, 723
mRNA, "lymphoid" chemokine expression in SS salivary glands, 408
Multiple sclerosis, demyelinating and neurologic events with TNFα antagonism, 1977
Muscarinic acetylcholine receptor, cleavage by granzyme B, 2376
Muscle strength, strength training in early RA, 515
Mutations. *See also* Gene transfer; Genetics; Polymorphisms
failure to verify H-*ras* mutations in arthritis synovium, 2705
hereditary angioedema, C1 inhibitor gene and, 974
methylene tetrahydrofolate reductase gene, and risk of MTX liver damage, 2525
SLE, T cell receptor gene, and polymorphisms, 1336
Mycoplasma pulmonis, defective Fas ligand-mediated apoptosis predisposes to arthritis after infection, 2146
Myositis, PMS1 is specific autoantigen, 389

N

Nasal, dosage of type II collagen in collagen-induced arthritis, 1917
Native American population
arthritis as predictor of cardiovascular disease-related death in Pima Indians, 1170
SSc, fibrillin 1 single-nucleotide polymorphism in Choctaws, 893
Natural killer (NK) cells
CD4+,CD28- T cells in RA, 13
IL-18 and death of, 884
Necrosis, autoantigen proteolysis in secondary necrosis, 2642
Neonates
congenital heart block, anti-Ro/SSA antibodies and, 1723, 1832
heart rate-corrected QT interval in children of anti-Ro-positive mothers, 242, 243
isolated congenital heart block in, 487, 647
Neovascularization, MMP-9, apoptosis, and vascular morphology in early arthritis, 2024
Neurofibromatosis, hemarthrosis in type 1, 2134
Neutralizing antibodies, adenovirus-mediated gene transfer in RA, synovial fluid and, 48
Neutrophils, ANCA promotes migration of through endothelium, 2851
Nitric oxide (NO)
mitochondrial respiration and functions of articular chondrocytes and, 96
OA, regulation by osteopontin in, 578
OA, selection of new therapeutic targets, 1240
OA, up-regulation of, in knee meniscus, 2078
peroxisome proliferator-activated receptor γ agonists inhibit chondrocyte activation, 595
SLE, circulating activated endothelial cells in, 1203
Nitric oxide synthase (NOS), deficiency of inducible NOS in murine antigen-induced arthritis, 1420
3-Nitrotyrosine, distribution in RA and normal synovium, 1534
Nonsteroidal antiinflammatory drugs (NSAIDs)
for AS, improvement criteria, 1876
flurbiprofen nitroxybutylester HCT1026 and bone resorption and bone loss, 2185
for OA, 1477
Notch-1 protein, activation of rheumatoid synoviocytes and, 1545
Nuclear factor κB (NF-κB)
CD95-induced apoptosis in human chondrocytes, 1644
inhibitor of, as regulator of synovial inflammation, 1897
RANKL in RA, 253, 1003
Nuclear orphan receptor, NURR1 and corticotropin-releasing hormone in arthritis, 782
Nucleoside triphosphate pyrophosphohydrolase, PC-1 in knee meniscal cartilage matrix calcification, 1071
Nucleosomes, plasma levels of, in murine lupus, 1320
NURR1, and corticotropin-releasing hormone in inflammatory arthritis, 782

O

Occupational exposure, SSc, cytochrome P2 polymorphisms and susceptibility in solvent-exposed individuals, 662
Oligoarthritis, predictors of outcome, 1177
Oncostatin M
  inhibition, arthritis amelioration in murine models, 2697
  synergistic induction of MMP-1 by IL-1α and, in chondrocytes, 2296
Oral tolerance, type II collagen, for RA, 1993
Organic solvents, SSc, cytochrome P2 polymorphisms and susceptibility in solvent-exposed individuals, 662
Osteoarthritis (OA)
  acetaminophen for alcoholic patients, 2449
  acetaminophen for patients with liver disease, 2448
  ACR recommendations for management, critiques, 2448, 2451, 2455
  acupuncture for knee, 819
  age-related changes in knee joint cartilage morphology and deformation, 2556
  age-related decrease in susceptibility of cartilage to MMP-mediated degradation, 2562
  antiapoptotic effect of hyaluronan, 1800
  apoptosis in cartilage, 1304
  C-C chemokines, receptors and, 1056
  cartilage intermediate-layer protein, role in arthropathy, 838
  cathepsin B in cartilage and chondrocytes, 1819
  CD8+ T cells in inflammatory arthritis joints, 2038
  cell clusters in rabbit meniscus, 1808
  diacerein for hip, ECHODIAH trial, 2539
  diclofenac plus misoprostol vs. acetaminophen, crossover clinical trial, 1587
  differentiated dendritic cell infiltration of synovial tissue, 105
  disintegrin MMP metargidin, expression in RA synovial tissue, 2046
  estrogen plus progestin, in postmenopausal women, 811
  familial hip, susceptibility locus on chromosome 16p, 2548
  fibroblast-mediated delivery of growth factor complementary DNA in mouse joints, 1943
  fibronectin, alternatively spliced EIIIA segment, 2572
  fluoroscopically directed steroid instillation in the hip, 2449
  gene expression pattern analysis in cartilage using complementary DNA-array technology, 277
  ginger for, 2461, 2531
  glucosamine and IL-1β in rat chondrocytes, 351
  glucosamine uptake in articular cartilage explants, 1089
  HOXD9 in synoviocyte proliferation, 1013
  human growth factor, involvement in cartilage, 73
  hylan G-F 20 for knee, 1470, 1471, 1473
  hylan G-F 20 injection, bilateral symmetric inflammatory reaction to, 978
  intraarticular glucocorticoids and joint damage mediators in synovium, 343
  knee, in elderly Chinese population, 2065
  knee, questionnaire screening for, 1105
  knee, radioanatomic alignment and progression of, 1786
  ML-3000, in vivo dual inhibition of COX and lipoxygenase by, 2320
  MMP and proinflammatory cytokine production by chondrocytes in, 585
  MMP-9, apoptosis, and vascular morphology in early disease, 2024
  MMPs and aggrecanase in lesions, 1455
  MRI assessment of cartilage loss in severe disease, 2072
  NSAID treatment for, 1477
  osteopontin, regulation of NO and prostaglandin E_2 by, 578
  osteoprotegerin receptor activator of RANKL, 2768
  PC-1 in knee meniscal cartilage matrix calcification, 1071
  placebo effects in pain trials, 1599
  power Doppler sonography and vascularity of synovial tissue in knee joint, 331
  selection of new therapeutic targets, 1237
  Sox9 and type IIA procollagen in mouse model, 947
Osteoarthritis (OA) *(cont'd)*
  up-regulation of NO and prostaglandin E_2 in meniscus, 2078
  $VEGF_{121}$ and $VEGF_{189}$ expression in cartilage, 1082
  VEGF serum level and destructive changes in inflammatory arthritis, 2055
  YKL-40 production by articular chondrocytes, regulation of, 826
Osteoblasts, inducible NOS pathway and inflammation-induced osteoporosis, 2790
Osteoclastogenesis, by activated T cells, in RA, 1003
Osteoclasts, clodronate mechanism of action, 2201
Osteopontin, regulation of NO and prostaglandin E_2 by, 578
Osteoporosis
  glucocorticoid-induced, prevention and treatment of, 1496
  glucocorticoids, alendronate in patients receiving, 202
  IL-6 gene polymorphism and bone resorption, 196
  inflammation-induced osteoporosis, 2790
  RA, inducible NOS-mediated osteoblast apoptosis and, 2790
  SLE, cardiovascular disease association in, 2338
Osteoprotegerin, in RA, 253, 1003
Osteoprotegerin receptor activator, of RANKL, 2768
Outcome. *See also* Mortality
  childhood HAQ functional outcome scores in JRA, 1768
  inflammatory polyarthritis, cigarette smoking and, 323
  inflammatory polyarthritis, disability and early treatment with DMARDs, 1033
  oligoarthritis, predictors of, 1177
  RA, ACR improvement criteria, 1052
  RA, independent association of RF and HLA-DRB1 shared epitope with radiographic outcome, 1529
  RA, Markov model for morbidity, mortality, and cost of care for, 2746
  RA, relationship between measures of outcome in, 2009
  SSc, penicillamine trial using disability index as predictor, 653
Oxidative stress, in SSc, 2653
Oxygen radicals, monocytic oxygen radical release induced by ANCA in vitro, 1698

P

P-selectin, adjuvant-induced arthritis in rats, 1428
p53, regulation of synovial fibroblast invasion by, mouse model of cartilage invasion, 676
Pain
  in fibromyalgia, somatization and, 751
  flare intensity and placebo responders in OA trials, 1599
  ginger extract in OA knee, 2531
  greater trochanteric pain syndrome, MRI and physical examination findings, 2138
  somatization as predictor of onset of chronic widespread pain, 940
  widespread musculoskeletal pain among twin pairs, 481
Parvovirus, B19-induced synoviocyte invasiveness in fibroblasts, 1582
Pathogens. *See also individual pathogen names*
  synovial fluid-PCR detection of, 2463
Penicillamine, high-dose vs. low-dose SSc trial, disability index as predictor of outcome, 653
Pentraxin, in small-vessel vasculitis, 2841
Periosteum-derived cells, chondrogenic potential and phenotypic stability throughout expansion, 85
Peripheral blood, RA, chemokine receptor expression on monocytes, 1022
Peripheral joints, hereditary angioedema, C1 inhibitor gene mutation and, 974
Peripheral nervous system, RA and, 493
Peroxisome proliferator-activated receptor γ, IL-1 induction of NO and MMP-13 in chondrocytes, 595
Phospholipase A_2, migration inhibitory factor, activation of RA synoviocytes, 1273
Pima Indians. *See* Native Americans

PMS1, as myositis-specific autoantigen, 389
Poetry, "Lupus wolf," 2214
Polley, Howard F., in memoriam, 1495
Polyarteritis nodosa
  long-term followup, 666
  silicone breast implants and, 2477
  treatment of, 508
Polyarthritis
  adult-onset Still's disease, IL-18 in, 550, 1716
  inflammatory, cigarette smoking and disease outcome, 323
  inflammatory, early treatment with DMARDs to reduce disability, 1033
  silicone breast implants and, 2477
Polychondritis, silicone breast implants and, 2477
Polymerase chain reaction (PCR), synovial fluid-PCR detection of pathogens, 2463
Polymorphisms. *See also* Gene transfer; Genetics; Mutations
  IL-6 gene, and bone resorption, 196
  IL-6 gene, single-base substitution by real-time PCR, 2213
  JIA, cytokine gene, and susceptibility to, 802
  JIA, IL-1Ra gene, in, 2387
  JIA, migration inhibitory factor, and systemic-onset JIA, 1782
  Kawasaki disease, monocyte chemoattractant protein 1, and serum levels in Japanese children, 2211
  RA, MHC class I chain-related gene A, 1261
  RA, single-nucleotide, in *SAA1* gene and risk of type AA amyloidosis in, 1266
  RA, TNFRII, 61
  Reactive arthritis, IL-10 microsatellites and, 1209, 2212
  SLE, prolactin gene, 2358
  SLE, T cell receptor gene, mutations and splice variations, 1336
  SLE, TNFRII, 196R association with, 2819
  SS, *Ro5*, 638
  SSc, cytochrome P2, and susceptibility in solvent-exposed individuals, 662
  SSc, cytochrome P2, and susceptibility to, 2705, 2706
  SSc, fibrillin 1 single-nucleotide, in Choctaw and Japanese populations, 893
Polymyalgia rheumatica
  inflamed structures with normal ESR, 1155
  silicone breast implants and, 2477
Polymyositis
  PMS1 is myositis-specific autoantigen, 389
  silicone breast implants and, 2477
Power Doppler sonography
  assessment of synovitis in MCP joints in RA, 2018
  vascularity of synovial tissue in OA and RA knee joint and, 331
Pregnancy
  APS, high rate of thrombosis after fetal loss, 1466
  APS, ICAM-1 expression and pregnancy loss, 1225
  APS, intravenous immunoglobulin in APS, 876
  SSc, fetal cell microchimerism in, 1848
Pro-matrix metalloproteinase 1 (proMMP-1), triptolide suppresses production of, in RA, 2193
Probes, erratum, Moos article (Nov. 2000), 1715
Procollagenase, activation of in cartilage breakdown, 2084
Progestin, OA knee symptoms in postmenopausal women and, 811
Prolactin, in SLE
  gene polymorphism and, 2358
  molecular heterogeneity of, 1331
Prolactin-IgG complex, in SLE, 866
Prostaglandins
  OA, regulation by osteopontin in, 578
  OA, up-regulation of NO and prostaglandin E_2 in knee meniscus, 2078
  SSc, enhanced lipid peroxidation in, 1143
Prostheses, aseptic loosening, in rat model, 956
Prostromelysin 1, triptolide suppresses production of, in RA, 2193
Protease genes, joint erosion in early RA and, 1744
Proteinase 3
  myeloperoxidase-ANCA and proteinase 3-ANCA to activate PMN cells in WG and microscopic polyangiitis, 921
  pro-proteinase 3-reactive ANCA and disease activity in WG and microscopic polyangiitis, 463
Protein kinase C, SSc lung fibroblasts and, 1370
Proteoglycan, FTIR spectral imaging of cartilage, 846
Proteoglycan-induced arthritis, susceptibility to, in C3H mice, 682
Proteolysis, autoantigen, in secondary necrosis, 2642
Psoriatic arthritis
  childhood HAQ functional outcome scores in children with, 1768
  corticotropin-releasing hormone, R1β, signaling via, in joint inflammation, 1761
  MMP-9, apoptosis, and vascular morphology in early disease, 2024
  oligoarthritis, predictors of outcome, 1177
  protease genes and erosion in early disease, 1744
  silicone breast implants and, 2477
  VEGF serum level and destructive changes in, 2055
PTX3, in small-vessel vasculitis, 2841
Pulmonary disease
  shrinking lung syndrome in patients without SLE, 243, 245
  SSc, protein kinase C and tenascin in fibroblasts, 1370
  SSc, pulmonary capillary endothelial dysfunction in, 902
  SSc, pulmonary hypertension, palliation by atrial septostomy, 1660
  SSc, renal crisis and pulmonary hypertension without interstitial lung disease, 1663
  SSc, surfactant protein D and pulmonary fibrosis in, 1363
Pulmonary fibroblasts. *See* Fibroblasts

Q

Quality of life, related to incident vertebral fractures, 2611

R

Rabbit models
  cell clusters in OA meniscus, 1808
  clodronate mechanism of action, 2201
  early degradation of types IX and II collagen in inflammatory arthritis, 120
  intraarticular liposomal clodronate in antigen-induced arthritis, 1908
  NO and mitochondrial respiration of articular chondrocytes, 96
  temporomandibular joint, cyclic tensile strain and effects of IL-1β in, 608
Radiography
  inflammatory polyarthritis, time to first occurrence of erosions in, 1248
  OA, radioanatomic alignment and progression of knee, 1786
  RA, independent association of RF and HLA-DRB1 shared epitope with radiographic outcome, 1529
  RA, prognostic factors for radiographic damage in early disease, 1736
RANTES, production by chondrocytes and role in cartilage degradation, 1633
Ras-MAPK signaling, decreased signaling causing DNA hypomethylation in T lymphocytes in SLE, 397
Rat models
  adjuvant-induced arthritis, SB 273005 in, 1428
  adjuvant-induced arthritis, selectins and, 1428
  aseptic prosthesis loosening, 956
  collagen-induced arthritis, amelioration by superoxide dismutase mimetic M40403, 2909
  collagen-induced arthritis, complement regulators and, 2425
  cysteine protease activity up-regulation and decrease with vinyl sulfone cysteine protease inhibitor, 703

Rat models *(cont'd)*
glucosamine and IL-1β in chondrocytes, 351
IKKβ as regulator of inflammation, 1897
RA, fractalkine in, and rat adjuvant-induced arthritis, 1568
Raynaud's phenomenon
calcium-channel blockers for, 1841
silicone breast implants and, 2477
Reactive arthritis
bacterial DNA in synovial tissue, 1689
Childhood HAQ functional outcome scores in children with, 1768
Chlamydia trachomatis -induced changes in, 2392
host defense scavenger receptors in, 931
IL-10 microsatellites and, 1209, 2212
oligoarthritis, predictors of outcome, 1177
synovial fluid-PCR detection of pathogens, 2463
Reactive oxygen species
monocytic oxygen radical release induced by ANCA in vitro, 1698
SSc, oxidative stress in, 2653
Receptor activator of NF-κB ligand (RANKL)
osteoprotegerin receptor activator of, 2768
in RA, 253, 1003
Recombinant IL-11, treatment of lupus-induced thrombocytopenia with, 170
Recombination-activating genes, in RA synovial tissue, 2275
Relapsing polychondritis
matrilin 1 antibodies in, 2402
orbital mucosa-associated lymphoid tissue-type lymphoma associated with, 1713
Reporter genes, fibroblast-specific regulatory elements in murine *Col1a2*, 712
Respiratory tract. *See also* Pulmonary
matrilin 1 antibodies in relapsing polychondritis, 2402
Rheumatic disease, Immune Tolerance Network, 1730
Rheumatoid arthritis (RA)
ACR 1987 criteria, 2485
ACR improvement criteria, 1052, 1719, 1720
activity loss and onset of depressive symptoms, 1194
adenoviral overexpression of TIMP-1 to reduce tissue damage, 2888
adenovirus-mediated gene transfer, synovial fluid and, 48
age-related decrease in susceptibility of cartilage to MMP-mediated degradation, 2562
amyloid fat deposits in, 66
anemia in, ferritin and serum transferrin receptor as predictors of iron deficiency, 979
anti-citrulline-containing peptide-producing B cells in synovial fluid, 41
anti-KIR autoantibodies in, 384
arthritis as predictor of cardiovascular disease-related death in, 1170
ATTRACT trial, paradox of beneficial treatment effects in responders in, 2703
autoimmunity and, 2218
B lymphocyte stimulator levels in, 1313
BiP in, 761
BMD change during first decade of disease, 1254
BMD in men with, 2941
Brown's syndrome, diplopia in, 2460
cardiovascular events not explained by traditional cardiac risk factors, 2737
cardiovascular mortality of, rheumatic disease role in, 2707
cartilage intermediate-layer protein, role in arthropathy, 838
cartilage turnover and inflammation in joints, 2503
6C2/GD3+ T cells in, 296
CD4+,CD28− T cells in, 13
CD8+ T cells in inflammatory arthritis joints, 2038
CD20+,CD38− B lymphocyte response in synovium, 2029
chemokine receptors, expression on monocytes, 1022
Rheumatoid arthritis (RA) *(cont'd)*
combination of TNFα blockade with IL-1 and IL-17 blockade for, 1293
corticotropin-releasing hormone signaling via corticotropin-releasing hormone receptor 1α in joint inflammation, 1761
cost of care, rheumatologists vs. generalists, 1504
C-reactive protein and, 995, 997
differentiated dendritic cell infiltration of synovial tissue, 105
disease activity, joint destruction, and functional capacity, 2009
disintegrin metalloproteinase MDC15 (metargidin) expression in synovial tissue, 2046
DRB1 molecules in, 1281
ErbB-2 in synovial cell growth, 260
etanercept for rheumatoid lymphedema, 240
Ets-1 expression in synovial membrane, 266
fibronectin, alternatively spliced EIIIA segment, 2572
FLIP expression and Fas-mediated apoptosis in synovial macrophages, 21
fractalkine in rat models, 1568
hepatitis B after MTX discontinuation, 339
high-dose chemotherapy and autologous stem cell transplantation in, 754
HLA haplotypes, 315
HLA-DQβ1 domain and anti-topoisomerase I autoantibody response, 491
HOXD9 in synoviocyte proliferation, 1013
hypothalamic-pituitary-adrenal/gonadal axis and peripheral nervous system in, 493
hypoxia-inducible factor 1α expression in, 1540
IL-8 and epithelial neutrophil activating peptide 78, angiogenesis regulation by, 31
IL-10 and IL-4 synergism in suppression of inflammation and joint destruction in, 3
IL-18 activity in joints, 275
Immune Tolerance Network, 1730
improvements in survival, 1467
indirect medical costs in early disease, 528
inflammation and damage in individual joints, 2243
infliximab therapy, hepatitis with interface inflammation and anti-double-stranded DNA antibodies, 1966, 1968
inheritance of, 2247
innate immune system in, 2224
intracellular citrullinated proteins in synovium, 2255
intravenous doxycycline therapy for, 1043
joint damage and MMP-1, MMP-3, and TIMP-1 serum levels in, 2263
leflunomide, compared with MTX, 1984, 1985
leflunomide-associated weight loss, 1048
lipoprotein markers, 2761
lymph draining from foot joints, cytokine and chemokine production and transport, 541
lymphocyte chemokine receptor expression in joints, 2750
macrophage inflammatory protein 1α, MMP-8, and systemic inflammation in, 2940
Markov model for morbidity, mortality, and cost of care for, 2746
measures of outcome in, 2009
methylene tetrahydrofolate reductase gene, C677T mutation in, 2525
MICA polymorphisms in, 1261
migration inhibitory factor, activation of synoviocytes, 1273
minocycline and hydroxychloroquine, comparison for early seropositive RA, 2235
MMP-9, apoptosis, and vascular morphology in early disease, 2024
MRI, of metacarpophalangeal joints, 2492
MTX, compared with leflunomide, 1984
MTX, effect of folate supplementation on therapy, 1515
3-nitrotyrosine, localization in synovium, 1534

Rheumatoid arthritis (RA) *(cont'd)*
NKT cells and, 1127
notch-1 protein and activation of synoviocytes and, 1545
osteoclastogenesis by activated T cells in, 1003
osteoporosis and inducible NOS-mediated osteoblast apoptosis, 2790
osteoprotegerin and RANKL in, 253
power Doppler sonography in assessment of synovitis in metacarpophalan geal joints, 2018
power Doppler sonography and vascularity of synovial tissue in knee joint, 331
premature mortality in, 1234
prognostic factors for radiographic damage in early disease, 1736
protease genes and joint erosion in early disease, 1744
protein kinase and TNFα-mediated apoptosis, 1555
radiographic joint damage in, 1231, 1736
recombination-activating genes and, 2275
RF and HLA-DRB1 shared epitope, independent association with radiographic outcome, 1529
Rheumatoid Arthritis Disease Activity Index, 53
shared epitope-negative HLA-DRB1 alleles and genetic susceptibility to, 535
silicone breast implants and, 2477
Single-nucleotide polymorphism in *SAA1* gene and risk of AA amyloidosis in, 1266
in smokers and nonsmokers, 2942
in Spanish population, 307
strength training and, 515
synergistic induction of MMP-1 by IL-1α and oncostatin M in chondrocytes, 2296
tenosynovium and tendon destruction in, 1754
therapy-induced lymphopenia, morbidity and mortality and, 1998
TNF and sex influences on HLA-associated RA risk, 286
TNFα antagonism, demyelinating and neurologic events with, 1977
TNFα blockade and pulse corticosteroid effects on, 245
TNFRII polymorphism and, 61
total lymphoid irradiation for, 1525
triptolide suppression of proMMP production, 2193
type 1 cytokine secretion by type II collagen-reactive T cells, 561
type II collagen, oral tolerance for, 1993
VCAM and joint inflammation, 985
VEGF expression by fibroblast-leukocyte interaction, 2512
VEGF serum level and destructive changes in, 2055
Wnt-5A signaling in, 772
Rheumatoid Arthritis Disease Activity Index, 53
Rheumatoid arthritis synovial fibroblasts, protein kinase Akt to regulate TNFα-mediated apoptosis of, 1555
Rheumatoid factor (RF), independent association of RF and HLA-DRB1 shared epitope with RA radiographic outcome, 1529
Rituximab, serum sickness with treatment, 1717
RNP antigens, ordering of human anti-RNP response, 368
Ro52 polymorphisms, in SS, 638

S

Salivary glands
SS, caspase 3 and Bax expression in, 693
SS, chronic sialadenitis treatment by *fasL* gene transfer in mice, 964
SS, immunoglobulin Vκ light chain gene analysis in, 626
SS, "lymphoid" chemokine mRNA expression in, 408
SS, monoclonal expansion of B cells in, 490
Salmonella typhimurium, alterations in HLA-B27-bound peptide alterations induced by, 1677
SB 273005, in rat adjuvant-induced arthritis, 128
Scavenger receptors, in spondylarthropathy, 931
Scleroderma. *See* Systemic sclerosis (SSc)
Screening instruments, questionnaire screening for knee OA, 1105
Secondary necrosis, autoantigen proteolysis in, 2642
Selectins, in rat adjuvant-induced arthritis, 1428
Serum sickness, with IDEC-C2B8 (rituximab) treatment, 1717
Serum transferrin receptor, as predictor of iron deficiency in anemia of RA, 979
Shared epitope
RA, independent association of RF and HLA-DRB1 shared epitope with radiographic outcome, 1529
RA, shared epitope-negative HLA-DRB1 alleles and genetic susceptibility to, 535
Shoulder, inflamed structures in polymyalgia rheumatica with normal ESR, 1155
Shrinking lung syndrome, in patients without SLE, 243, 245
Sibling studies. *See* Family studies
Signal transducer and activator of transcription (STAT), synergistic induction of MMP-1 by IL-1α and oncostatin M in, 2296
Signaling
CD95 signaling in human chondrocytes, 1644
RA, notch-1 protein, activation of rheumatoid synoviocytes and, 1545
RA, Wnt-5A signaling in, 772
SLE, decreased Ras-MAPK signaling causing DNA hypomethylation in T lymphocytes in, 397
SLE, FcεRIγ in, 1114
SLE, T cell receptor gene mutations/polymorphisms and splice variations, 1336
Silicone breast implants, rheumatologic disorders and, 2477
Single-nucleotide polymorphisms, in *SAA1* gene and risk of AA amyloidosis in RA, 1266
Single-nucleotide promoters, IL-10 microsatellites and reactive arthritis, 1209, 2212
Sjögren's syndrome (SS)
autoantigen α-fodrin and type 3 muscarinic acetylcholine receptor cleavage by granzyme B, 2376
B cell-attracting chemokine 1 (CXCL13) in, 2633
caspase 3 and Bax expression in, 693
chronic sialadenitis treatment by *fasL* gene transfer in mice, 964
IL-10 haplotypes in, 176
immunoglobulin V_{δ} light chain gene usage in, 2620
immunoglobulin Vκ light chain gene analysis in, 626
infliximab therapy for, 2371 "lymphoid" chemokine mRNA expression in, 408
monoclonal expansion of B cells in, 490
mothers of children with isolated heart block, 647
NKT cells and, 1127
peripheral blood dendritic cells, alteration of in, 419
Ro52 polymorphisms in, 638
silicone breast implants and, 2477
Skin. *See also* Fibroblasts
desensitization to allopurinol following cutaneous reactions, 231
fetal cell trafficking and dermal fibrosis, 2944
IL-17 synergizes with TNFα and fine-tunes IL-1, IL-6, and IL-8, 2176
SSc, improvement in skin thickening associated with improved survival, 2828
SSc, 5-lipoxygenase overexpression in skin, 1865
Sleep, alpha characteristics in fibromyalgia, 222
Small-vessel vasculitis
monocytic oxygen radical release induced by ANCA, 1698
PTX3 in, 2841
surrounding spared temporal artery, 1387
$SmD1^{83\text{-}119}$ peptide, strong acceleration of murine lupus by injection of, 2435
Smoking
early inflammatory polyarthritis and, 323
RA and, 2942
Socioeconomic status, rheumatology and health of workforce, 1971

Somatization
pain in fibromyalgia and, 751
as predictor of onset of chronic widespread pain, 940
Spanish population, RA in, 307
Spinal cord
cervical spinal cord compression, 241
vertebral fracture, effect of alendronate on in patients receiving glucocorticoids, 202
Splicing
OA, cathepsin B in cartilage and cultured chondrocytes, 1819
SLE, T cell receptor gene mutations/polymorphisms and splice variations, 1336
Spondylarthropathy
anti-TNFα, effects on synovium in, 186, 2937, 2938
AS, celecoxib for, 180
AS, risk of in first-born children, 1964, 1965
Childhood HAQ functional outcome scores in children with, 1768
differentiated dendritic cell infiltration of synovial tissue, 105
etanercept for entheseal pathology in resistant disease, 2112
host defense scavenger receptors in, 931
inflammatory bowel disease and, 2728
thalidomide in severe refractory seronegative, 2456, 2457
Spondylitis
Brucella spondylitis, 2939
susceptibility of C3H mice, 682
Statins, endothelial activation mediated by anti-β_2-glycoprotein I, statin inhibition, 2870
Steroid-induced osteoporosis, prevention and treatment of, 1496
Still's disease, IL-18 in adult-onset disease, 550, 1716
Stress proteins, overexpression of BiP in RA, 761
Stromelysin, MMPs in Lyme arthritis, 1401
Superoxide dismutase
mimetic M40403 and collagen-induced arthritis, 2909
treatment of murine collagen-induced arthritis with extracellular gene transfer, 2160
Surfactant protein D, pulmonary fibrosis in SSc and, 1363
Susceptibility
age-related decrease in susceptibility of cartilage to MMP-mediated degradation, 2562
Behçet's disease, mapping novel susceptibility locus for to chromosome 6p22-23, 2693
JIA, gene polymorphisms and, 802
OA, susceptibility locus on chromosome 16p in familial hip OA, 2548
proteoglycan-induced arthritis and spondylitis in C3H mice, 682
RA, shared epitope-negative HLA-DRB1 alleles and genetic susceptibility to, 535
SLE, linkage analysis of traits, 2807
SSc, cytochrome P2 polymorphisms and, 662, 2705, 2706
Synergism, IL-10 and IL-4 in suppression of inflammation and joint destruction in, RA, 3
Synovial fibroblasts. *See also* Fibroblasts
Synovial fluid
adenovirus-mediated gene transfer and, 48
CD8+ T cells in inflammatory arthritis joints, 2038
Chlamydia and *Borrelia* DNA in synovial fluid of early undifferentiated oligoarthritis, 2679
early degradation of types IX and II collagen in experimental inflammatory arthritis, 120
fibronectin, alternatively spliced EIIIA segment, 2572
MMP-9, apoptosis, and vascular morphology in early arthritis, 2024
MMPs in Lyme arthritis, 1401
PCR detection of pathogens, 2463
RA, anti-citrulline-containing peptide-producing B cells in, 41
RA, 6C2/GD3+ T cells in, 296
RA, cartilage turnover and inflammation in joints, 2503
RA, CD20+,CD38− B lymphocyte response in synovium, 2029
Synovial fluid *(cont'd)*
RA, chemokine receptor expression on monocytes, 1022
RA, VEGF expression by fibroblast-leukocyte interaction, 2512
LE cells in, 169
Synovial membrane
mesenchymal stem cells from, 1928
MMP-9, apoptosis, and vascular morphology in early arthritis, 2024
Synovial tissue
Ad5.fib16 vectors for gene transfer to, 570
anti-TNFα, effect on synovium in spondylarthropathy, 186, 2937, 2938
bacterial DNA in, 1689
Behçet's disease, oligoclonal B lymphocyte expansion in, 1707
blastomycosis-induced arthritis, 492
corticotropin-releasing hormone signaling via corticotropin-releasing hormone receptor 1α in joint inflammation, 1761
failure to verify H-*ras* mutations in, 2705
glucosamine uptake in articular cartilage explants, 1089
hypoxia-inducible factor 1α expression in, 1540
IKKβ as regulator of inflammation, 1897
JRA, correlation with revascularization of human synovium engrafted into SCID mice, 794
Lyme arthritis, in vitro model of, 151
3-nitrotyrosine distribution in, 1534
OA, differentiated dendritic cell in, 105
OA, intraarticular glucocorticoids and joint damage mediators in, 343
RA, angiogenesis regulation by IL-8 and epithelial neutrophil activating peptide 78 in, 31
RA, chemokine receptor expression on monocytes, 1022
RA, combination of TNFα blockade with IL-1 and IL-17 blockade for, 1293
RA, disintegrin metalloproteinase MDC15 (metargidin) expression in, 2046
RA, ErbB-2 in synovial cell growth, 260
RA, Ets-1 expression in, 266
RA, FLIP expression and Fas-mediated apoptosis in synovial macrophages, 21
RA, IFNγ-inducing activity of IL-18 in, 275
RA, intracellular citrullinated proteins in, 2255
RA, protease genes and joint erosion in early disease, 1744
RA, protein kinase Akt to regulate TNFα-mediated apoptosis of fibroblasts, 1555
RA, recombination-activating genes and, 2275
RA, vascularity of knee joint, correlation with power Doppler sonography, 331
RA, Wnt-5A signaling in, 773
regulation of synovial fibroblast invasion by p53, 676
spondylarthropathy, anti-TNFα effects on, 186, 2937, 2938
stimulatory protein fragments copurifying with woodchuck hepatitis virus, 486
Synovial-like interface membrane, aseptic prosthesis loosening, rat model, 956
Synoviocytes
HOXD9 in proliferation, 1013
human parvovirus B19-induced invasiveness in fibroblasts, 1582
migration inhibitory factor, regulation of synoviocyte phospholipase A_2 and COX-2 by, 1273
notch-1 protein and activation in RA, 1545
Synovitis
familial Mediterranean fever, musculoskeletal manifestations of, 1416
polymyalgia rheumatica, inflamed shoulder structures in with normal ESR, 1155
RA, power Doppler sonography in assessment of in metacarpophalangeal joints, 2018

Systemic autoimmune disease
autoantigen proteolysis in secondary necrosis, 2642
B lymphocyte stimulator levels in, 1313
IL-18 and NK cell death in, 884
immunoglobulin variable-region gene usage in, 2715
KIR autoantibodies in, 384
silicone breast implants and, 2477
Systemic idiopathic vasculitis, disease activity and survival in, 2943
Systemic lupus erythematosus (SLE)
anti-DNA-based peptide, mouse model, 432
anti-dsDNA during flare, 2342
anti-KIR autoantibodies in, 384
anti-Ku autoantibodies in, 2367
anti-topoisomerase I (anti-Scl-70) antibodies in, 376
APS, lupus band test yields negative results in, 488
atherosclerosis and, 2215, 2331
autologous stem cell transplantation for refractory childhood disease, 728
B lymphocyte stimulator levels in, 1313
C1 inhibitor deficiency and, 1836
C3 and C4 levels drop with renal and hematologic disease, 2350
circulating activated endothelial cells in, 1203
COX-2 inhibition and thrombosis, 984
dendritic cell alterations in, 856
DNA hypomethylation by decreased signaling in, 397
DNase activity in, 2446
EBV exposure and, 1122
FcεRIγ in, 1114
flare following GM-CSF treatment, 2458, 2459
glutathione S-transferase null alleles and, 981
health disparities in, 2711
hydroxychloroquine macular toxicity during treatment, 1959
Immune Tolerance Network, 1730
immunoadsorption with C1q column, 1962
immunologic laboratory tests in, 2221
LE cells in kidney and synovial fluid, 169
Libman-Sacks endocarditis, 2111
linkage analysis of SLE-related traits, 2807
low-binding Fcγ alleles in, 361
lupus nephritis, Fcγ receptor IIIA-158F allele as risk factor for, 618
micro- and macrovascular AECA, 1484
microchimerism in, 2107
NKT cells and, 1127
nucleosome kinetics, mouse model, 1320
osteoporosis and cardiovascular disease in, 2338
predictors of damage in LUMINA cohort, 2797
prolactin, molecular heterogeneity of in, 1331
prolactin gene polymorphism and, 2358
prolactin-IgG complex in, 866
recombinant human IL-11 for thrombocytopenia induced by, 170
silicone breast implants and, 2477
SmD1$^{83\text{-}119}$ peptide, strong acceleration of murine lupus by injection of, 2435
T cell receptor gene mutations/polymorphisms and splice variations, 1336
Th1 immune response in diffuse proliferative lupus nephritis, 2097
TNFα blockade and, 1721, 1722
TNFRII polymorphism 196R association with, 2819
Systemic sclerosis (SSc)
ACR preliminary SSc classification criteria, 735
anti-topoisomerase I antibodies, loss of and antiidiotypes, 737
blockade of endogenous TGFβ in fibroblasts, 474
cytochrome P2 polymorphisms and susceptibility to, 662, 2705, 2706
decreased apoptosis in fibroblasts, 1667
enhanced lipid peroxidation in, 1143
familial occurrence frequency, 1359
fetal cell microchimerism in, 1848
Systemic sclerosis (SSc) *(cont'd)*
fibrillin 1 in, 893, 1855
fibroblast-specific regulatory elements in murine *Col1a2,* 712
high-dose vs. low-dose penicillamine trial, disability index as predictor of outcome, 653
HLA-DQβ1 domain and anti-topoisomerase I autoantibody response, 491
improvement in skin thickening and improved survival, 2828
5-lipoxygenase overexpression in skin, 1865
micro- and macrovascular AECA, 1484
microchimerism in, 1226
monocyte chemoattractant protein 1 in, 1382, 2665
MTX in early disease, 1351
NKT cells and, 1127
oxidative stress in, 2653
protein kinase C and tenascin in lung fibroblasts, 1370
pulmonary capillary endothelial dysfunction in, 902
pulmonary hypertension, palliation by atrial septostomy, 1660
Raynaud's phenomenon in, calcium-channel blockers for, 1841
renal crisis and pulmonary hypertension without interstitial lung disease, 1663
silicone breast implants and, 2477
surfactant protein D and pulmonary fibrosis in, 1363
TGFβ receptors, up-regulated expression of in dermal fibroblasts, 731
topoisomerase I-reactive T cells in twins, 1654

T

T cell receptor gene mutations/polymorphisms and splice variations in SLE, 1336
T cells
CD8+ in inflammatory arthritis joints, 2038
Churg-Strauss syndrome, IL-4 and IL-13 production by, 469
defective Fas ligand-mediated apoptosis of after *Mycoplasma pulmonis* infection, 2146
murine lupus, anti-DNA-based peptide in, 432
RA, BiP overexpression in, 761
RA, 6C2/GD3+ T cells in, 296
RA, CD4+,CD28− T cells in, 13
RA, osteoclastogenesis by, 1003
RA, type 1 cytokine secretion by type II collagen-reactive T cells in, 561
SLE, DNA hypomethylation by decreased signaling in, 397
SLE, FcεRIγ in, 1114
SSc, topoisomerase I-reactive T cells in twins, 1654
Temporal artery biopsy, small-vessel vasculitis surrounding spared temporal artery, 1387
Temporomandibular joint, cyclic tensile strain and effects of IL-1β in, 608 •
Tenascin, SSc lung fibroblasts and, 1370
Tendon destruction in RA, cytokines, VEGF, MMPs, and TIMP-1 and, 1754
Tenosynovitis, Brown's syndrome, and diplopia in RA, 2460
Terminal deoxynucleotidyl transferase, in RA synovial tissue, 2275
Tetracyclines, intravenous doxycycline therapy for RA, 1043
Th1 immune response, in diffuse proliferative lupus nephritis, 2097
Thalidomide, in severe refractory seronegative spondylarthropathy, 2456, 2457
Thrombocytopenia, SLE-induced, recombinant human IL-11 for, 170
Thrombosis
APS, aspirin for high thrombosis rate after fetal loss, 1466
APS, intravenous immunoglobulin in, 876
APS, tissue factor in, 2467
COX-2 inhibition and, 984, 1229, 1230
TIA-1, TNFα regulation by in macrophages, 2879
Tissue factor, APS and, 2467

Tissue inhibitors of metalloproteinases (TIMPs)
adenoviral overexpression of to reduce tissue damage, 2888
collagen-induced arthritis, TIMP-1 gene transfer in, 1444
RA, cartilage turnover and inflammation in joints, 2503
RA, MMP-1, MMP-3, and TIMP-1 serum levels in, 2263
RA, production of TIMP-1 by tenosynovium and tendon destruction, 1754
RA, triptolide suppression of proMMP production in, 2193
Tolerance
Immune Tolerance Network, 1730
type II collagen nasal dosage in suppression of collagen-induced arthritis, 1917
type II collagen oral tolerance for RA, 1993
Topoisomerase I, topo I-reactive T cells in SSc twins, 1654
Total lymphoid irradiation, for RA, 1525
Tracheolaryngeal cartilage, matrilin 1 antibodies in, in relapsing polychondritis, 2402
Transcription factors
NURR1 and corticotropin-releasing hormone in arthritis, 782
Sox9 and type IIA procollagen in murine OA, 947
Transforming growth factor β (TGFβ)
SSc, blockade of endogenous TGFβ in fibroblasts, 474
SSc, up-regulated expression of TGFβ in dermal fibroblasts, 731
Transmission disequilibrium test, Behçet's disease, linkage of HLA-B locus in, 239
Trendelenburg's sign, in greater trochanteric pain syndrome, 2138
Tripterygium wilfordii Hook. f., triptolide suppression of proMMP production in RA, 2193
Triptolide, proMMP production suppressed by, 2193
Triterpenoids, CDDO inhibition of MMP-1 and MMP-13 induction, 1096
Trochanteric bursitis, MRI and physical examination in, 2138
Tumor necrosis factor α (TNFα)
blockade and SLE, 1721, 1722
cyclic tensile strain inhibits TNFα-induced genes in articular chondrocytes, 2311
IL-17 synergizes with, and fine-tunes IL-1, IL-6, and IL-8, 2176
RA, combination of TNFα blockade with IL-1 and IL-17 blockade for, 1293
RA, protein kinase Akt to regulate TNFα-mediated apoptosis of synovial fibroblasts, 1555
RA, TNFα blockade and pulse corticosteroid effects, 245
resistant spondylarthropathy, etanercept for entheseal pathology, 2122
TIA-1 to regulate production of in macrophages, 2879
Tumor necrosis factor α (TNFα) antagonism
demyelination during therapy, 2862
RA, demyelinating and neurologic events with, 1977
Tumor necrosis factor (TNF) markers, sex-influenced association with RA, 286
Tumor necrosis factor receptor II (TNFRII)
polymorphism 196R association with SLE, 2819
polymorphism of and RA in Caucasians, 61
Turkish population
Behçet's disease, linkage of HLA-B locus in, 239
Behçet's disease, mapping novel susceptibility locus to chromosome 6p22-23 in, 2693
Twin studies
topoisomerase I-reactive T cells in SSc, 1654
widespread musculoskeletal pain, 481
Type 1 neurofibromatosis, hemarthrosis in, 2134
Type 3 muscarinic acetylcholine receptor, cleavage by granzyme B, 2376

U

Ultrasonography, for diagnosis and management of musculoskeletal conditions, 2932
Undifferentiated arthritis
Chlamydia and *Borrelia* DNA in synovial fluid in early disease, 2679
oligoarthritis, predictors of outcome, 1177
Uveitis, etanercept therapy in children with treatment-resistant disease, 1411

V

Vascular cell adhesion molecule 1 (VCAM-1), joint inflammation and, 985
Vascular endothelial growth factor (VEGF)
decay-accelerating factor induction by, 138
RA, production by tenosynovium and tendon destruction, 1754
RA, VEGF expression by fibroblast-leukocyte interaction, 2512
serum level and destructive changes in inflammatory arthritis, 2055
$VEGF_{121}$ and $VEGF_{189}$ expression in OA cartilage, 1082
Vasculitis, disease activity and survival in, 2943
Vertebral fracture
effect of alendronate in patients receiving glucocorticoids, 202
health-related quality of life and, 2611
Vinyl sulfone cysteine protease inhibitor, cysteine protease activity up-regulation in adjuvant-induced arthritis, 703
Vitronectin receptor antagonists, SB 273005 in rat adjuvant-induced arthritis, 128
von Recklinghausen's disease, hemarthrosis in, 2134

W

Wegener's granulomatosis (WG)
anti-CD20 chimeric monoclonal antibody therapy, 2836
Birmingham Vasculitis Activity Score for, 912
classification criteria, differentiation from Churg-Strauss syndrome by artificial neural network, 1887
etanercept combined with conventional treatment in, 1149
myeloperoxidase-ANCA and proteinase-3-ANCA to activate PMN in, 921
proteinase 3-reactive ANCA and disease activity in, 463
silicone breast implants and, 2477
Weight loss, leflunomide-associated, in RA, 1048
Widespread musculoskeletal pain
somatization as predictor of onset, 940
in twin pairs, 481
Woodchuck hepatitis virus, synovial stimulatory protein fragments copurifying with, 486
Workforce, rheumatology and health of, 1971
Wrist, hereditary angioedema, C1 inhibitor gene mutation and, 974

Y

YKL-40, regulation of production by articular chondrocytes, 826